<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006301.pub4" GROUP_ID="CHILDCA" ID="155006060616112501" MERGED_FROM="" MODIFIED="2015-10-01 11:03:35 +0100" MODIFIED_BY="Jos Noorman" REVIEW_NO="002" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2015-10-01 11:30:38 +0200" MODIFIED_BY="Edith Leclercq">
<TITLE MODIFIED="2010-04-09 10:01:12 +0200" MODIFIED_BY="[Empty name]">High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma</TITLE>
<CONTACT>
<PERSON ID="B012C0FD82E26AA200D5E26B75BB7ECA" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Bilgehan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Yalçin</LAST_NAME>
<SUFFIX/>
<POSITION>Prof. of Pediatrics and Pediatric Oncologist</POSITION>
<EMAIL_1>yalcinb@hacettepe.edu.tr</EMAIL_1>
<EMAIL_2>bilgehanyalcin@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pediatric Oncology</DEPARTMENT>
<ORGANISATION>Hacettepe University Faculty of Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ankara</CITY>
<ZIP>06100</ZIP>
<REGION/>
<COUNTRY CODE="TR">Turkey</COUNTRY>
<PHONE_1>+90 312 305 2990</PHONE_1>
<PHONE_2>+90 312 305 2986</PHONE_2>
<FAX_1>+90 312 310 7018</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-10-01 11:30:38 +0200" MODIFIED_BY="Edith Leclercq">
<PERSON ID="B012C0FD82E26AA200D5E26B75BB7ECA" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Bilgehan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Yalçin</LAST_NAME>
<SUFFIX/>
<POSITION>Prof. of Pediatrics and Pediatric Oncologist</POSITION>
<EMAIL_1>yalcinb@hacettepe.edu.tr</EMAIL_1>
<EMAIL_2>bilgehanyalcin@yahoo.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Pediatric Oncology</DEPARTMENT>
<ORGANISATION>Hacettepe University Faculty of Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ankara</CITY>
<ZIP>06100</ZIP>
<REGION/>
<COUNTRY CODE="TR">Turkey</COUNTRY>
<PHONE_1>+90 312 305 2990</PHONE_1>
<PHONE_2>+90 312 305 2986</PHONE_2>
<FAX_1>+90 312 310 7018</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13704" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Leontien</FIRST_NAME>
<MIDDLE_INITIALS>CM</MIDDLE_INITIALS>
<LAST_NAME>Kremer</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>l.c.kremer@amc.uva.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT>
<ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION>
<ADDRESS_1>PO Box 22660</ADDRESS_1>
<ADDRESS_2/>
<CITY>Amsterdam</CITY>
<ZIP>1100 DD</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 20 5667132</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13729" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Elvira</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>van Dalen</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>e.c.vandalen@amc.uva.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT>
<ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION>
<ADDRESS_1>PO Box 22660 (room TKsO-247)</ADDRESS_1>
<ADDRESS_2/>
<CITY>Amsterdam</CITY>
<ZIP>1100 DD</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 20 5665697</PHONE_1>
<PHONE_2/>
<FAX_1>+ 31 20 5669021</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-06-24 10:38:20 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="12" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="12" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="5" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-07-14 14:13:48 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-07-14 14:13:43 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>Summary of most important changes in the update:</P>
<P>The search for eligible studies was updated to December 2014.</P>
<P>No new RCTs were identified, but we did identify an erratum for one of the already included studies. Based on data provided in the erratum a descriptive result of overall survival at 5 years changed from significantly different in favour of the myeloablative therapy group to not significantly different between treatment groups, which is in accordance with our overall analysis.</P>
<P>For the risk of bias assessment we now used the most recent recommendations of the Childhood Cancer Group. All studies were re-assessed using the new criteria. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-07-14 14:13:48 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to December 2014.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-06-24 10:50:50 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-06-24 10:50:50 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Summary of most important changes in the update:</P>
<P>The search for eligible studies was updated to June 2012. Additional follow-up data of one of the three already included RCTs were available. For overall survival the results changed from a significant difference in favour of myeloablative therapy into no significant difference between the treatment groups.</P>
<P>It should be noted that all included studies used an age of one year as the cut-off point for pre-treatment risk stratification. Recently the age cut-off for high risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate risk disease have been included in the high risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-24 10:50:48 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to June 2012. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-09-04 12:17:33 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2009-09-04 12:17:33 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-09-04 12:17:08 +0200" MODIFIED_BY="[Empty name]">
<NAME>Foundation of Pediatric Cancer Research (SKK) Amsterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-09-04 12:17:33 +0200" MODIFIED_BY="[Empty name]">
<NAME>Stichting Kinderen Kankervrij (KIKA)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-09-29 14:14:49 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-09-29 14:14:49 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-08-19 13:54:29 +0200" MODIFIED_BY="[Empty name]">High-dose chemotherapy and stem cell transplant compared to conventional therapy for children with high-risk neuroblastoma</TITLE>
<SUMMARY_BODY MODIFIED="2015-09-29 14:14:49 +0200" MODIFIED_BY="[Empty name]">
<P>Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients still remains poor; in more than half of patients the disease returns. Stem cell rescue replaces blood-forming stem cells that were destroyed by high-dose chemotherapy in order to recover the bone marrow. It is also known as myeloablative therapy and might improve the survival of these patients. A well-informed decision on the use of myeloablative therapy in the treatment of children with high-risk neuroblastoma should be based on high quality evidence of effectiveness for treating tumours and side effects.</P>
<P>This systematic review focused on randomised studies comparing the effectiveness of myeloablative therapy with conventional therapy in children with high-risk neuroblastoma. The authors found three studies including 739 patients. These studies provide evidence that myeloablative therapy improves event-free survival (that is, the time until a certain event, for example tumour progression, the development of a second tumour, or death from any cause occurs). For overall survival (that is, the time until a patient dies from any cause, so not only from the tumour or its treatment, but for example, also from a car accident) there is no evidence of a better outcome in patients treated with myeloablative therapy. Side effects such as renal (kidney) effects, interstitial pneumonitis (a type of lung disease) and veno-occlusive disease (a condition in which some of the small veins in the liver are obstructed) were more common in patients treated with myeloablative therapy than conventional chemotherapy. It should be noted that this systematic review only allows a conclusion on the concept of myeloablative therapy; no conclusions regarding the best treatment strategy with regard to, for example, types of chemotherapeutic agents and the use of radiation therapy, could be made. More high quality research is needed.</P>
<P>It should be noted that recently the age cut-off for high-risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate-risk disease were included in the high-risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate-risk disease.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-29 13:51:23 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-07-14 14:14:36 +0200" MODIFIED_BY="[Empty name]">
<P>Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence. High-dose chemotherapy and haematopoietic stem cell rescue (i.e. myeloablative therapy) might improve survival. This review is the second update of a previously published Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-09-29 13:21:08 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary objective</B>
</P>
<P>To compare the efficacy, that is event-free and overall survival, of high-dose chemotherapy and autologous bone marrow or stem cell rescue with conventional therapy in children with high-risk neuroblastoma.</P>
<P>
<B>Secondary objectives</B>
</P>
<P>To determine adverse effects (e.g. veno-occlusive disease of the liver) and late effects (e.g. endocrine disorders or secondary malignancies) related to the procedure and possible effects of these procedures on quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-29 13:20:57 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the electronic databases The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2014, issue 11), MEDLINE/PubMed (1966 to December 2014) and EMBASE/Ovid (1980 to December 2014). In addition, we searched reference lists of relevant articles and the conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2002 to 2014), American Society for Pediatric Hematology and Oncology (ASPHO) (from 2002 to 2014), Advances in Neuroblastoma Research (ANR) (from 2002 to 2014) and American Society for Clinical Oncology (ASCO) (from 2008 to 2014). We searched for ongoing trials by scanning the ISRCTN register (www.isrct.com) and the National Institute of Health Register (www.clinicaltrials.gov). Both registers were screened in April 2015.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-08-19 13:54:01 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing the efficacy of myeloablative therapy with conventional therapy in high-risk neuroblastoma patients.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-08-19 13:31:37 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently performed study selection, data extraction and risk of bias assessment. If appropriate, we pooled studies. The risk ratio (RR) and 95% confidence interval (CI) was calculated for dichotomous outcomes. For the assessment of survival data, we calculated the hazard ratio (HR) and 95% CI. We used Parmar's method if hazard ratios were not reported in the study. We used a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-29 13:51:23 +0200" MODIFIED_BY="[Empty name]">
<P>We identified three RCTs including 739 children. They all used an age of one year as the cut-off point for pre-treatment risk stratification. The first updated search identified a manuscript reporting additional follow-up data for one of these RCTs, while the second update identified an erratum of this study. There was a significant statistical difference in event-free survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (three studies, 739 patients; HR 0.78, 95% CI 0.67 to 0.90). There was a significant statistical difference in overall survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (two studies, 360 patients; HR 0.74, 95% CI 0.57 to 0.98). However, when additional follow-up data were included in the analyses the difference in event-free survival remained statistically significant (three studies, 739 patients; HR 0.79, 95% CI 0.70 to 0.90), but the difference in overall survival was no longer statistically significant (two studies, 360 patients; HR 0.86, 95% CI 0.73 to 1.01). The meta-analysis of secondary malignant disease and treatment-related death did not show any significant statistical differences between the treatment groups. Data from one study (379 patients) showed a significantly higher incidence of renal effects, interstitial pneumonitis and veno-occlusive disease in the myeloablative group compared to conventional chemotherapy, whereas for serious infections and sepsis no significant difference between the treatment groups was identified. No information on quality of life was reported. In the individual studies we evaluated different subgroups, but the results were not univocal in all studies. All studies had some methodological limitations.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-08-19 13:36:03 +0200" MODIFIED_BY="[Empty name]">
<P>Based on the currently available evidence, myeloablative therapy seems to work in terms of event-free survival. For overall survival there is currently no evidence of effect when additional follow-up data are included. No definitive conclusions can be made regarding adverse effects and quality of life, although possible higher levels of adverse effects should be kept in mind. A definitive conclusion regarding the effect of myeloablative therapy in different subgroups is not possible. This systematic review only allows a conclusion on the concept of myeloablative therapy; no conclusions can be made regarding the best treatment strategy. Future trials on the use of myeloablative therapy for high-risk neuroblastoma should focus on identifying the most optimal induction and/or myeloablative regimen. The best study design to answer these questions is a RCT. These RCTs should be performed in homogeneous study populations (e.g. stage of disease and patient age) and have a long-term follow-up. Different risk groups, using the most recent definitions, should be taken into account.</P>
<P>It should be kept in mind that recently the age cut-off for high risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate-risk disease have been included in the high-risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate-risk disease.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-29 14:00:22 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-09-29 13:23:07 +0200" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-09-29 13:23:07 +0200" MODIFIED_BY="[Empty name]">
<P>Neuroblastoma is the most common extracranial solid tumour in children comprising 8% to 10% of all childhood cancers. The incidence is nearly 10 per 1,000,000 children under the age of 15 years and 90% of cases are diagnosed in the first 10 years of life. Children with neuroblastoma mostly present with abdominal disease and more than half of the cases have advanced disease (defined as stage III or IV disease) (<LINK REF="REF-Aydin-2009" TYPE="REFERENCE">Aydin 2009</LINK>; <LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>).</P>
<P>Neuroblastoma is one of the most challenging and enigmatic neoplasms of childhood because of its biological heterogeneity and contrasting patterns of clinical behaviour. Some young infants with favourable disease may experience complete spontaneous regression while older children with metastatic disease mostly relapse despite initial response to chemotherapy.</P>
<P>The prognosis and management of children with neuroblastoma is highly dependent on clinical, histopathological and biological characteristics, and they are stratified into risk groups based on prognostic factors (<LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Maris-2005" TYPE="REFERENCE">Maris 2005</LINK>; <LINK REF="REF-Maris-2007" TYPE="REFERENCE">Maris 2007</LINK>; <LINK REF="REF-Weinstein-2003" TYPE="REFERENCE">Weinstein 2003</LINK>). For pre-treatment risk stratification traditionally an age of one year was used as a cut-off point. The low-risk disease group included cases younger than one year who had stage I, II or IV-S disease with favourable histopathology and no MYCN oncogene amplification (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Maris-2005" TYPE="REFERENCE">Maris 2005</LINK>; <LINK REF="REF-Maris-2007" TYPE="REFERENCE">Maris 2007</LINK>; <LINK REF="REF-Weinstein-2003" TYPE="REFERENCE">Weinstein 2003</LINK>).</P>
<P>High-risk neuroblastoma cases were traditionally characterised by an age older than one year, disseminated disease, MYCN oncogene amplification and unfavourable histopathologic findings (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Maris-2005" TYPE="REFERENCE">Maris 2005</LINK>; <LINK REF="REF-Weinstein-2003" TYPE="REFERENCE">Weinstein 2003</LINK>). However, in recent years a new neuroblastoma risk classification system has been developed by the International Neuroblastoma Risk Group (INRG) Task Force resulting in standardised approaches for the initial evaluation and treatment stratification of neuroblastoma patients (<LINK REF="REF-Cohn-2009" TYPE="REFERENCE">Cohn 2009</LINK>). In this INRG classification system an age cut-off of 18 months is used for pre-treatment risk stratification, as opposed to the traditional cut-off of one year. In many of the currently published studies patients with what is now understood to be intermediate-risk disease were classified as high-risk patients. Consequently the relevance of the results of these studies to current practice can be questioned.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-07-14 14:15:38 +0200" MODIFIED_BY="[Empty name]">
<P>Substantial improvement has been achieved in the cure of patients with low-risk neuroblastoma resulting in survival rates up to 90% (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>). In high-risk cases, despite intensified combination chemotherapies, surgery, radiotherapy and the use of differentiation agents, prognosis improved only modestly with long-term survival in less than one-third of patients (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-De-Bernardi-2003" TYPE="REFERENCE">De Bernardi 2003</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Weinstein-2003" TYPE="REFERENCE">Weinstein 2003</LINK>; <LINK REF="REF-Peinemann-2015a" TYPE="REFERENCE">Peinemann 2015a</LINK>). In the last two decades higher remission rates have been achieved with intensive induction chemotherapy regimens combined with surgical resection, external irradiation or both (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Castel-1995" TYPE="REFERENCE">Castel 1995</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Kaneko-2002" TYPE="REFERENCE">Kaneko 2002</LINK>; <LINK REF="REF-Kushner-2004" TYPE="REFERENCE">Kushner 2004</LINK>; <LINK REF="REF-Laprie-2004" TYPE="REFERENCE">Laprie 2004</LINK>; <LINK REF="STD-Sawaguchi-1990" TYPE="STUDY">Sawaguchi 1990</LINK>). The effects of retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation are currently not clear (<LINK REF="REF-Peinemann-2015b" TYPE="REFERENCE">Peinemann 2015b</LINK>).</P>
<P>The challenge is to maintain remission since more than half of patients with high-risk disease develop systemic disease recurrence with or without a relapse at the primary tumour site (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Matthay-1993" TYPE="REFERENCE">Matthay 1993</LINK>; <LINK REF="REF-Weinstein-2003" TYPE="REFERENCE">Weinstein 2003</LINK>). AntiGD2 antibody-based immunotherapy has been shown to improve event-free and overall survival in high-risk neuroblastoma patients in remission after multimodality treatment (<LINK REF="REF-Yu-2010" TYPE="REFERENCE">Yu 2010</LINK>). Therapy failures are mostly attributed to development of resistance to chemotherapy and minimal residual disease is considered an important cause of recurrence (<LINK REF="REF-Burchill-2004" TYPE="REFERENCE">Burchill 2004</LINK>; <LINK REF="REF-Keshelava-1998" TYPE="REFERENCE">Keshelava 1998</LINK>; <LINK REF="REF-Reynolds-2001" TYPE="REFERENCE">Reynolds 2001</LINK>; <LINK REF="REF-Reynolds-2004" TYPE="REFERENCE">Reynolds 2004</LINK>).</P>
<P>The idea that further increasing dose intensity may overcome chemotherapy resistance has provided a rationale for aggressive high-dose chemotherapy consolidation protocols (<LINK REF="REF-Cheung-1991" TYPE="REFERENCE">Cheung 1991</LINK>; <LINK REF="REF-Pritchard-1995" TYPE="REFERENCE">Pritchard 1995</LINK>). Such myeloablative chemotherapy regimens utilise effective high-dose drug combinations which can be safely escalated to levels above those causing bone marrow ablation. Rapid bone marrow reconstitution can be achieved by autologous stem cell rescue. Autologous peripheral blood stem cells (PBSC) are the preferred source for rescue as this has several advantages over autologous bone marrow grafts. For example, the procedure of PBSC collection is easier, the incidence of tumour cell contamination is lower, and the yield of stem cells is higher (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Cohn-1997" TYPE="REFERENCE">Cohn 1997</LINK>; <LINK REF="REF-Ladenstein-1994" TYPE="REFERENCE">Ladenstein 1994</LINK>). A possible limitation of using autologous products is the risk of tumour cell contamination in the graft, which has been shown to contribute to relapse. Considerable efforts have been made to detect and remove tumour (negative purging) or select progenitor cells (positive purging) before reinfusion (<LINK REF="REF-Ladenstein-2004" TYPE="REFERENCE">Ladenstein 2004</LINK>). Disease status prior to stem cell rescue has a crucial influence on final outcome. Patients in complete, very good partial or partial remission have a better prognosis, while those with stable disease or no response have a poor outcome (<LINK REF="REF-Ladenstein-2004" TYPE="REFERENCE">Ladenstein 2004</LINK>).</P>
<P>Patients undergoing stem cell rescue may experience toxicities related to conditioning regimens like veno-occlusive disease of the liver or haemorrhagic cystitis (<LINK REF="REF-Bollard-2006" TYPE="REFERENCE">Bollard 2006</LINK>). Growth failure, endocrine disorders such as gonadal or thyroid dysfunction, hearing impairment, renal impairment, orthopedic complications as well as the occurrence of secondary malignancies are among the late complications following high-dose chemotherapy and stem cell rescue (<LINK REF="REF-Bollard-2006" TYPE="REFERENCE">Bollard 2006</LINK>; <LINK REF="REF-Trahair-2007" TYPE="REFERENCE">Trahair 2007</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-07-14 14:15:39 +0200" MODIFIED_BY="[Empty name]">
<P>Many retrospective and prospective non-randomised studies support the use of a myeloablative consolidation in neuroblastoma. Retrospective studies mostly suggest that intensification of consolidation therapy with autologous stem cell rescue following high-dose chemotherapy improves survival (<LINK REF="REF-Castel-1995" TYPE="REFERENCE">Castel 1995</LINK>; <LINK REF="REF-Di-Caro-1994" TYPE="REFERENCE">Di Caro 1994</LINK>; <LINK REF="STD-Matthay-1995" TYPE="STUDY">Matthay 1995</LINK>; <LINK REF="REF-Philip-1997" TYPE="REFERENCE">Philip 1997</LINK>; <LINK REF="STD-Stram-1996" TYPE="STUDY">Stram 1996</LINK>; <LINK REF="REF-Verdeguer-2004" TYPE="REFERENCE">Verdeguer 2004</LINK>). The results of non-randomised pilot studies by the Children's Cancer Group also suggest a modest prolongation of event-free survival for children with high-risk neuroblastoma (<LINK REF="STD-Matthay-1995" TYPE="STUDY">Matthay 1995</LINK>).</P>
<P>This is the second update of the first systematic review evaluating the current state of evidence on the efficacy of high-dose chemotherapy and autologous haematopoietic stem cell rescue compared with conventional therapy in patients diagnosed with high-risk neuroblastoma (<LINK REF="REF-Yal_x00e7_in-2010" TYPE="REFERENCE">Yalçin 2010</LINK>; <LINK REF="REF-Yal_x00e7_in-2013" TYPE="REFERENCE">Yalçin 2013</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-09-29 13:23:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary objective</B>
</P>
<P>To compare the efficacy, that is event-free and overall survival, of high-dose chemotherapy and autologous bone marrow or stem cell rescue with conventional therapy in children with high-risk neuroblastoma.</P>
<P>
<B>Secondary objectives</B>
</P>
<P>To determine adverse effects (e.g. veno-occlusive disease of the liver) and late effects (e.g. endocrine disorders or secondary malignancies) related to the procedure and possible effects of these procedures on quality of life.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-29 13:33:54 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-09-28 09:15:10 +0200" MODIFIED_BY="Denise M Mitchell">
<CRIT_STUDIES MODIFIED="2015-09-28 09:15:10 +0200" MODIFIED_BY="Denise M Mitchell">
<P>Randomised controlled trials (RCTs) that compared the efficacy of high-dose chemotherapy and autologous bone marrow or stem cell rescue with conventional therapy were considered for inclusion.<BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-08-19 11:42:26 +0200" MODIFIED_BY="[Empty name]">
<P>Participants included children (aged &lt; 21 years) with high-risk neuroblastoma. High-risk neuroblastoma is defined as a combination of the following characteristics: unfavourable age (as defined by the authors of the included studies), advanced stage disease (as defined by the authors of the included studies), presence of MYCN oncogene amplification, or unfavourable histopathologic findings (as defined by the authors of the included studies) or both. Recently the age cut-off for high-risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate-risk disease were included in the high-risk group.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-08-19 11:43:10 +0200" MODIFIED_BY="[Empty name]">
<P>Interventions included high-dose chemotherapy with autologous bone marrow or stem cell rescue versus conventional therapy (i.e. either conventional chemotherapy or no further treatment). High-dose chemotherapy is defined as chemotherapy sufficient to require stem cell rescue. Conventional chemotherapy is defined as chemotherapy at a lower dose than the high-dose chemotherapy without the need for stem cell rescue.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-08-19 11:43:22 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-08-16 20:38:58 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Event-free survival (usually defined as the time to recurrence or progression of disease or death from any cause or varying definitions, as used by the authors).</LI>
<LI>Overall survival (defined as the time to death from any cause).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-08-19 11:43:22 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Adverse events (e.g. stomatitis, diarrhoea, fatigue, anaemia, leukopenia, thrombocytopenia or veno-occlusive disease of the liver) and late effects (e.g. endocrine disorders or secondary malignancies).</LI>
<LI>Quality of life.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-07-14 14:15:54 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2014, issue 11), MEDLINE/PubMed (from 1966 to December 2014) and EMBASE/Ovid (from 1980 to December 2014). The search strategies for the different electronic databases (using a combination of controlled vocabulary and text word terms) are shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.<BR/>
</P>
<P>We located information about trials not registered in CENTRAL, MEDLINE or EMBASE, either published or unpublished, by searching the reference lists of relevant articles and review articles. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP) (from 2002 to 2014), the American Society for Pediatric Hematology and Oncology (ASPHO) (from 2002 to 2014), Advances in Neuroblastoma Research (ANR) (from 2002 to 2014) and the American Society for Clinical Oncology (ASCO) (from 2008 to 2014), if available electronically and otherwise by handsearching. We searched for ongoing trials by scanning the ISRCTN register (www.isrct.com) and the National Institute of Health Register (www.clinicaltrials.gov). Both registers were screened in April 2015. We imposed no language restriction.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-29 13:33:54 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-06-24 11:46:30 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened the search results to identify studies meeting the inclusion criteria. We obtained full manuscripts for any study that appeared to meet the inclusion criteria based on title, or abstract or both for closer inspection. We clearly reported reasons for exclusion for any study considered for the review. Discrepancies between authors were resolved by consensus. No third party arbitration was needed.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-06-24 11:46:44 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data using standardised forms. We extracted the following data:</P>
<UL>
<LI>the characteristics of the participants at the time of randomisation (such as age, sex, stage of disease, histology, MYCN oncogene amplification, received induction treatment, received external irradiation, remission status at myeloablative treatment and stem cell rescue);</LI>
<LI>the characteristics of interventions (details of myeloablative therapy: drugs used, routes of delivery, dose, timing, use of total body irradiation; details of the stem cell rescue: timing and methods of cell harvest, timing of stem cell rescue, number of cells infused, contamination with tumour cells);</LI>
<LI>details of supportive care (such as the use of prophylactic antibiotics, growth factors, granulocyte infusions);</LI>
<LI>details of outcome measures as described above; and</LI>
<LI>length of follow up.</LI>
</UL>
<P>In case of disagreement between authors, we re-examined the abstracts and articles and discussed these until consensus was achieved. No third party arbitration was needed.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-29 13:23:15 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently performed assessment of risk of bias in the included studies. For this second update we used the most recent recommendations of the Childhood Cancer Group (that is selection bias, performance bias, detection bias (for each outcome separately), attrition bias (for each outcome separately), reporting bias and other bias). We used the 'risk of bias' items and definitions of low risk, unclear risk and high risk as described in the module of the Cochrane Childhood Cancer Group (<LINK REF="REF-Kremer-2014" TYPE="REFERENCE">Kremer 2014</LINK>), which is based on the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). All RCTs were scored using the new 'risk of bias' items. Discrepancies between authors were resolved by consensus. No third party arbitration was needed. The risk of bias in the included studies was taken into account in the interpretation of the review's results.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-06-24 12:13:27 +0200" MODIFIED_BY="[Empty name]">
<P>The risk ratio (RR) was calculated for dichotomous outcomes along with the corresponding 95% confidence interval (CI). For the assessment of survival, we used the generic inverse variance function of RevMan to combine logs of the hazard ratios (HR) and estimate corresponding 95% CI. We used Parmar's method if hazard ratios were not reported in the study (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>).</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-09-29 13:23:42 +0200" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity, i.e. the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If there was evidence of substantial heterogeneity (I² &gt; 50%), this was reported.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-29 13:28:35 +0200" MODIFIED_BY="[Empty name]">
<P>In addition to the evaluation of reporting bias, as described in the <A HREF="https://archie.cochrane.org/sections/documents/view?document=z1303141340359211704887320346721&amp;format=REVMAN#QUALITY_ASSESSMENT">Assessment of risk of bias in included studies</A> section, we planned to construct a funnel plot to graphically ascertain the existence of publication bias. However, as a rule of thumb, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta-analysis, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>). Since only three trials could be included in the review, we did not construct funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-09-29 13:33:49 +0200" MODIFIED_BY="[Empty name]">
<P>We entered data into Review Manager (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and analysed data according to the guidelines of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). We pooled studies for meta-analysis when appropriate. We extracted data by allocation intervention, irrespective of compliance with the allocated intervention, in order to allow for an 'intention-to-treat' (ITT) analysis. We used a random-effects model for the estimation of treatment effects throughout the review. Where possible, we presented data separately for different prognostic factors such as disease status at the time of stem cell rescue, MYCN amplification status and serum lactate dehydrogenase levels. For outcomes where only one study was available, we were unable to calculate a RR if one of the treatment groups experienced no events and the Fischer&#8217;s exact test was used instead; this option is not available in RevMan and therefore we used http://graphpad.com/quickcalcs/contingency2/.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-29 13:33:54 +0200" MODIFIED_BY="[Empty name]">
<P>For all outcomes for which pooling was possible we performed sensitivity analyses for all quality criteria separately. We excluded low quality studies and studies for which the quality was unclear, and compared the results of the good quality studies with the results of all available studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-29 13:57:48 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-09-29 13:34:13 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-09-29 13:34:13 +0200" MODIFIED_BY="[Empty name]">
<P>We ran searches of the electronic databases CENTRAL, MEDLINE/PubMed and EMBASE/Ovid in January 2009 for the original version of this review. This search yielded a total of 1463 references. Initial screening excluded 1427 references which clearly did not meet all the criteria for considering studies for this review. We obtained 36 references in full for closer inspection. Three studies fulfilled all the criteria for considering studies for this review and were included in the review (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). We excluded the remaining 33 articles for reasons described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>For the first update we ran searches of CENTRAL, MEDLINE/PubMed and EMBASE/Ovid in June 2012 yielding a total of 266 references which were added to the search results from January 2009. Initial screening excluded 265 references which clearly did not meet the inclusion criteria. We obtained one full-text study for closer inspection. It fulfilled the inclusion criteria and was thus included. This study provides additional follow-up data for the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study.</P>
<P>For the second update we ran searches of CENTRAL, MEDLINE/PubMed and EMBASE/Ovid in December 2014 yielding a total of 313 references. Initial screening excluded all 313 references; no studies needed to be seen in full text.</P>
<P>We scanned the reference lists of relevant articles and reviews and conference proceedings (i.e. SIOP, ASPHO and ASCO) and did not identify any additional eligible studies. One trial was added to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. By scanning the ANR conference proceedings we identified one study that has not yet been published in full and is awaiting further assessment (see <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table). This study provides additional follow-up for the <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> study. We identified an erratum on one of the included studies (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). No eligible ongoing trials were identified.</P>
<P>In summary, the total number of included RCTs was three (described in four publications and one erratum). Characteristics of included studies are summarised below (for further details see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). We also identified one study awaiting assessment.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-06-24 12:48:18 +0200" MODIFIED_BY="[Empty name]">
<P>All three eligible RCTs were multi-centre studies, two of which were based in Europe (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>) and one in North America (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). Patients were recruited between January 1982 (<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>) and November 2002 (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>). The total number of patients included in the three studies was 739; 370 children received high-dose chemotherapy and stem cell rescue, whereas 369 children received either conventional chemotherapy (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>) or no further treatment (<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). All trials used different induction regimens (i.e. different chemotherapeutic agents and different (cumulative) dosages) and different myeloablative treatments. In <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> and <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> there were also differences in treatment patients received in the study itself (for example, external radiotherapy, therapeutic MIBG-I<SUP>131</SUP>, immunotherapy and retinoic acid treatment). See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for further details. All patients were diagnosed with high-risk neuroblastoma. The definitions of high-risk neuroblastoma differed between studies (See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> included newly diagnosed patients. It was unclear if the patients in the other studies were newly diagnosed. None of the studies reported the exact age of the participants; only the number of cases above and below one year of age was reported.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-09-28 10:17:55 +0200" MODIFIED_BY="Denise M Mitchell">
<P> See the risk of bias section of the <A HREF="https://archie.cochrane.org/sections/documents/view?document=A92329C382E26AA2016292A43EF809F0&amp;format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES">Characteristics of included studies</A> table and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for the exact scores per included study. 
<BR/>
</P>
<ALLOCATION MODIFIED="2015-07-14 14:16:21 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating selection bias we have assessed the random sequence generation and the allocation concealment. The risk of selection bias was low in two studies (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>), while in one study it was unclear (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). </P>
</ALLOCATION>
<BLINDING MODIFIED="2015-09-28 10:17:55 +0200" MODIFIED_BY="Denise M Mitchell">
<P>For evaluating performance bias we have assessed the blinding of participants and personnel. In two studies there was a high risk of bias (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>), while in one study it was unclear (<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). However, it should be noted that due to the nature of the interventions blinding of care providers and patients was virtually impossible.</P>
<P>For evaluating detection bias we have evaluated the blinding of outcome assessors for all separate outcomes, with the exception of overall survival since for that outcome blinding is not relevant and the risk of detection bias was thus automatically judged as low for all three studies evaluating this outcome. All three studies evaluated event-free survival; in two studies the risk of detection bias was unclear (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>), while in the other study it was low (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). However, for the additional follow-up data of this study it became unclear. Two studies evaluated adverse effects; in one study the risk of detection bias was unclear (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>), while in the other study it was low (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). However, again, for the additional follow-up data of this study it was unclear if the outcome assessor evaluating adverse events was blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-07-14 14:16:45 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating attrition bias we have assessed incomplete outcome data for all separate outcomes. Three studies evaluated both event-free and overall survival; in all studies the risk of attrition bias was unclear. Two studies evaluated adverse effects other than treatment-related death; in both studies the risk of attrition bias was unclear (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). Two studies evaluated treatment-related death; in one study the risk of attrition bias was low (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>), while in the other study it was high (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-07-14 14:16:49 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating reporting bias we have assessed selective reporting. We defined 'all expected outcomes' as reporting on event-free survival, overall survival and early and late adverse effects (irrespective of the number of evaluated adverse effects; for studies presenting additional follow-up only late adverse effects were considered appropriate). In one study we judged the risk of reporting bias to be low (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>), while in two studies it was judged to be high (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-07-14 14:16:52 +0200" MODIFIED_BY="[Empty name]">
<P>For evaluating other potential sources of bias we have assessed the difference in length of follow-up between treatment arms and inappropriate influence of funders. In all three studies there was an unclear risk of other bias. For a more detailed description of the different items see the risk of bias section of the <A HREF="http://www.archie.cochrane.org/sections/documents/view?document=60533348873545919391101216111740&amp;format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES">Characteristics of included studies</A> table.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-09-29 13:57:48 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Event-free survival</HEADING>
<P>Data on event-free survival were extracted from three trials (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>) with a total of 739 patients (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Two of these trials included secondary malignant disease as an event (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>), whereas the other did not (<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>; see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for the exact definitions). However, since only a very small percentage of patients developed secondary malignant disease (see the description of adverse effects later on), we were able to pool the results of these three trials. There was a significant statistical difference in event-free survival in favour of myeloablative therapy over conventional chemotherapy or no further treatment (HR 0.78, 95% CI 0.67 to 0.90, P = 0.0006). No heterogeneity was detected for this comparison (I<SUP>2 </SUP>= 0%).</P>
<P>The meta-analysis of the two trials including secondary malignant disease as an event also showed a significant statistical difference in event-free survival in favour of myeloablative therapy over conventional chemotherapy (HR 0.79; 95% CI 0.67 to 0.92, P = 0.002, 674 patients). No heterogeneity was detected for this comparison (I<SUP>2 </SUP>= 0%). The study not including secondary malignant disease as an event showed no significant statistical difference between myeloablative therapy and no further treatment (HR 0.73, 95% CI 0.49 to 1.07, P = 0.11, 65 patients).</P>
<P>Additional follow-up data from the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study have been published. The length of follow-up was not reported, but the median follow-up of patients alive without an event was 7.7 years (range 130 days to 12.8 years). Relapse was included as an event in the follow-up study, as opposed to the original publication. The results of this meta-analysis of three trials including additional follow-up data were in line with the earlier data. There was a significant statistical difference in event-free survival in favour of the myeloablative therapy group over conventional chemotherapy or no further treatment (HR 0.79, 95% CI 0.70 to 0.90, P = 0.0003, 739 patients). No heterogeneity was detected for this comparison (I<SUP>2 </SUP>= 0%). When additional follow-up data were included the meta-analysis of the two trials including secondary malignant disease as an event again showed a significant statistical difference in event-free survival in favour of the myeloablative therapy group over conventional chemotherapy (HR 0.80, 95% CI 0.70 to 0.92, P = 0.001, 674 patients). No heterogeneity was detected for this comparison (I<SUP>2 </SUP>= 0%). The results of the analysis of the study not including secondary malignant disease as an event did not change, since no new data were available (i.e. no significant difference between the treatment groups). See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<P>The above mentioned HRs were calculated using the complete follow-up period of the trials. The individual studies also reported three or five-year event-free survival rates. <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> and <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> reported significantly better three-year event-free survival rates in the myeloablative therapy group compared to conventional chemotherapy (P = 0.0221 and P = 0.034 respectively). <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> found no significant statistical difference in five-year event-free survival between the treatment groups (P = 0.08). Additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> showed a significant statistical difference in five-year event-free survival in favour of the myeloablative therapy group (P = 0.0434).</P>
<P>It should be noted that the individual studies all used different starting points for event-free survival, either years since randomisation or years from diagnosis. In the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study randomisation was performed a median of 60 days after diagnosis. <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> did not report the time of randomisation but the decision to randomise was made five to nine months after diagnosis. In the <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> study randomisation was performed a median of 39 days after diagnosis.</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroups</HEADING>
<P>Subgroups are summarised descriptively (i.e. as reported in the individual studies).</P>
<P>
<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> performed subgroup analyses based on commonly accepted risk factors. Three-year event-free survival was significantly better in the myeloablative therapy group compared to conventional chemotherapy: (1) in patients who had a complete remission or very good partial remission to induction chemotherapy/before randomisation (P = 0.0083); (2) in patients with raised serum concentration of lactate dehydrogenase (P = 0.0357; cut-off value not reported); and (3) in patients receiving antibody treatment (P = 0.0061). By contrast, no significant statistical difference in three-year event-free survival was identified between the treatment groups: (1) in patients who had partial remission, mixed remission or stable disease before randomisation (P = 0.1809); (2) in patients treated with retinoic acid (P = 0.9732); (3) in patients with MYCN amplification with stage I, II, III, or IV-S disease or with stage IV disease aged younger than one year (P = 0.2183); (4) in patients with MYCN amplification (P = 0.0669); (5) in patients without MYCN amplification (P = 0.0643); (6) in patients with normal concentrations of serum lactate dehydrogenase (P = 0.3132; cut-off value not mentioned); and (7) in patients with stage IV disease and age more than one year (P = 0.0549).</P>
<P>
<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> performed subgroup analyses based on stage IV disease, MYCN amplification, unfavourable histopathological findings, a serum ferritin level of at least 143 ng per millilitre, a partial response to initial chemotherapy (as compared to complete response or nearly complete response), age at diagnosis more than two years and, among stage IV patients, bone metastases at diagnosis, and the presence at diagnosis of more than 100 tumour cells per 10<SUP>5</SUP> normal nucleated bone marrow cells. <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> reported that event-free survival among patients assigned to myeloablative therapy was longer in each subgroup (univariate analysis) than that among patients assigned to conventional chemotherapy (no P values reported). This difference in event-free survival was most pronounced among the subgroups of patients who were older than two years at diagnosis (P = 0.01) and among patients with MYCN amplification (P = 0.03). Additional follow-up data showed no significant statistical difference between treatment groups in event-free survival in patients with stage IV disease.</P>
<P>
<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> reported significantly better five-year event-free survival in patients aged more than one year with stage IV disease assigned to the myeloablative therapy group (P = 0.01).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Overall survival</HEADING>
<P>Data on overall survival were reported in three trials (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). The results from two of these trials could be pooled (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). There was a significant statistical difference in overall survival in favour of the myeloablative therapy group over conventional chemotherapy or no further treatment (HR 0.74, 95% CI 0.57 to 0.98, P = 0.04, 360 patients). No heterogeneity was detected for this comparison (I<SUP>2 </SUP>= 0%). See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. The other study (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>) only provided descriptive results: overall survival was similar for both regimens (379 patients).</P>
<P>As opposed to the original publication, the additional follow-up data from the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study included information on overall survival. The length of follow-up was not mentioned, but the median follow-up of patients alive without an event was 7.7 years (range 130 days to 12.8 years). In contrast to the earlier results, the meta-analysis including the additional follow-up data showed no significant statistical difference in overall survival between treatment groups (HR = 0.86, 95% CI 0.73 to 1.01, P = 0.06, 739 patients). No heterogeneity was detected (I<SUP>2</SUP> = 0%) (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>The above mentioned HR is calculated using the complete follow-up period of the trials. The individual studies also reported three- or five-year overall survival rates. <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> and <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> found no significant statistical difference in three-year overall survival between the treatment groups (P = 0.0875 and P = 0.87 respectively). <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> found no significant statistical difference in five-year overall survival between the treatment groups (P = 0.1). Additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> showed no significant statistical difference in five-year overall survival between the treatment groups (P = 0.3917). As opposed to the data provided in the additional follow-up publication (at five years overall survival was significantly better in the myeloablative therapy group compared to the conventional chemotherapy group), in the erratum it was stated that at five years the overall survival curves were not significantly different (P = 0.08).</P>
<P>It should be noted that the individual studies all used different starting points for overall survival, either years since randomisation or years from diagnosis. In the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study randomisation was performed a median of 60 days after diagnosis. <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> did not report the time of randomisation but the decision to randomise was made five to nine months after diagnosis. In the Berthold 2005 study randomisation was performed a median of 39 days after diagnosis.</P>
<SUBSECTION>
<HEADING LEVEL="4">Subgroups</HEADING>
<P>Subgroups are summarised descriptively (i.e. as reported in the individual studies).</P>
<P>
<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> performed subgroup analyses based on commonly accepted risk factors. Three-year overall survival was significantly better in the myeloablative therapy group compared to conventional chemotherapy: (1) in patients who had a complete remission or very good partial remission before randomisation (P = 0.0436), or (2) in patients receiving antibody treatment (P = 0.0221). By contrast, no significant difference in three-year event-free survival was identified between the treatment groups in the following subgroups: (1) in patients who had partial remission, mixed remission or stable disease before randomisation (P = 0.1311); (2) in patients treated with retinoic acid (P = 0.8918); (3) in patients with MYCN amplification with stage I, II, III or IV-S disease or with stage IV disease aged younger than one year (P = 0.2287); (4) in patients with MYCN amplification (P = 0.1658); (5) in patients without MYCN amplification (P = 0.1921); (6) in patients with normal concentrations of serum lactate dehydrogenase (P = 0.1985; cut-off value not reported); (7) in patients with raised serum concentration of lactate dehydrogenase (P = 0.1247; cut-off value not reported); and (8) in patients with stage IV disease and aged more than one year (P = 0.1820).</P>
<P>
<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> did not report any subgroup analyses regarding overall survival in the original manuscript. Using additional follow-up data a subgroup analysis of patients with stage IV disease found no significant statistical difference in overall survival between the treatment groups.</P>
<P>
<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> reported that five-year overall survival in patients aged more than one year with stage IV disease was significantly better in the myeloablative therapy group than in the no further treatment group (P = 0.03).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Since all patients receiving antineoplastic treatment will suffer from adverse events, we decided to analyse only severe and life-threatening effects. We defined this as toxicity grade three or higher. Only adverse effects occurring from the start of the randomised treatment (i.e. myeloablative therapy or control) were eligible for inclusion in this review. See <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Treatment-related death</HEADING>
<P>Data on treatment-related death could be extracted from two trials with a total of 574 patients (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). There were 12 deaths among 278 patients randomised to the myeloablative therapy group and five among 296 in the control group. There was no significant statistical difference in treatment-related death between the treatment groups (RR 2.53, 95% CI 0.17 to 37.12, P = 0.50). However, unexplained heterogeneity was detected (I<SUP>2 </SUP>= 78%). It should be noted that it was not possible to perform an ITT analysis using the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> data, therefore we performed an as-treated analysis.</P>
<P>When additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> were included in the meta-analysis there was still no significant statistical difference in treatment-related death between the treatment groups (RR 1.08, 95% CI 0.65 to 1.78, P = 0.78). There were 25 deaths among 271 patients in the myeloablative group compared to 26 among 284 patients in the control group (RR 1.08, 95% CI 0.65 to 1.78, P = 0.78). No unexplained heterogeneity was detected for this comparison (I<SUP>2</SUP> = 0%). Again, it was not possible to perform an ITT analysis for the study of Matthay 1999, so an as-treated analysis was performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary malignant disease</HEADING>
<P>Data on secondary malignant disease could be extracted from two trials with a total of 674 patients (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). There were two cases of secondary malignant disease among 338 patients in the myeloablative group (i.e. one acute myeloid leukaemia and one unknown malignancy) compared to two cases among 336 conventional chemotherapy patients (i.e. one acute lymphoblastic leukaemia and one unknown malignancy). The meta-analysis showed no significant statistical difference between the treatment groups (RR 0.99; 95% CI 0.14 to 7.00, P = 0.99). No heterogeneity was detected for this comparison (I<SUP>2 </SUP>= 0%).</P>
<P>When additional follow-up data from the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study were included in the meta-analysis there was still no significant statistical difference between the treatment groups (RR 1.48, 95% CI 0.24 to 9.01, P = 0.67). There were three cases of secondary malignant disease among 338 patients in the myeloablative therapy group (i.e. two cases of acute myeloid leukaemia and one follicular carcinoma of the thyroid) compared to two among 336 patients in the conventional chemotherapy group (i.e. both acute lymphoblastic leukaemia). No unexplained heterogeneity was detected for this comparison (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other adverse effects</HEADING>
<P>Data on serious infections, sepsis, renal effects, interstitial pneumonitis and veno-occlusive disease could be extracted from one trial with a total of 379 patients (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). There was a significantly higher incidence of renal effects, interstitial pneumonitis and veno-occlusive disease in the myeloablative group compared to conventional chemotherapy, whereas for serious infections and sepsis no significant difference between the treatment groups was identified (see <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> for more information; since for veno-occlusive disease none of the 190 patients in the control group experienced an event (while 17 out of 189 patients in the myeloablative therapy group did), we used the Fischer's exact test; P = 0.0001). These toxicity data did not change with additional follow-up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>None of the studies evaluated quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>The results of the sensitivity analyses for the risk of bias criteria were consistent among the trials and did not differ from the overall analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-29 14:00:07 +0200" MODIFIED_BY="[Empty name]">
<P>Neuroblastoma is the most common extracranial solid tumour in children. Unfortunately, despite the development of new treatment options, the prognosis of high-risk patients is poor; and disease recurs in more than half of patients (<LINK REF="REF-Brodeur-2006" TYPE="REFERENCE">Brodeur 2006</LINK>; <LINK REF="REF-Goldsby-2004" TYPE="REFERENCE">Goldsby 2004</LINK>; <LINK REF="REF-Matthay-1993" TYPE="REFERENCE">Matthay 1993</LINK>; <LINK REF="REF-Weinstein-2003" TYPE="REFERENCE">Weinstein 2003</LINK>). High-dose chemotherapy and stem cell transplantation might increase survival in these patients. This systematic review evaluated the current state of evidence on the efficacy of high-dose chemotherapy and autologous haematopoietic stem cell rescue compared with conventional therapy in patients diagnosed with high-risk neuroblastoma. Only randomised controlled trials (RCTs) were included since it is widely recognised that a RCT is the only study design which can be used to obtain unbiased evidence on the use of different treatment options, provided that the design and execution of the RCTs are adequate.</P>
<P>We identified three RCTs that compared high-dose chemotherapy and autologous haematopoietic stem cell rescue (i.e. myeloablative therapy) with conventional chemotherapy or no further treatment (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). The first updated literature search identified a manuscript reporting additional follow-up data from the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study and the second one an erratum for this study. The exact length of follow-up was not reported, but the median follow-up of patients alive without an event was 7.7 years (range 130 days to 12.8 years). Even though all patients were diagnosed with high-risk neuroblastoma, definitions of high-risk patients differed between the studies, as did the required response to induction therapy to be eligible for randomisation. The three included RCTs used an age of one year as the cut-off point for pre-treatment risk stratification. Recently the age cut-off for high-risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate-risk disease were included in the high-risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be overestimated due to the inclusion of patients with intermediate-risk disease. Randomisation was performed at different time intervals since diagnosis. All trials used different induction treatments, myeloablative treatments and control treatments. Also, in two trials the received treatment slightly differed between patients, but we assumed that as a result of randomisation these differences in treatment were evenly distributed in both treatment groups. Two studies used bone marrow cells (<LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>; <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>) and one study used peripheral blood cells (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>) for stem cell transplant (See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for further information).</P>
<P>The individual studies reported three or five-year event-free survival. In the <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> and <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> studies (including the additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>) a significant statistical difference in favour of myeloablative therapy was identified. In the <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK> study this difference was not statistically significant. Our meta-analysis using their complete follow-up period also showed a significant statistical difference in event-free survival in favour of the myeloablative therapy group (HR 0.78, 95% CI 0.67 to 0.90, P = 0.0006). When the two studies in which secondary malignant disease was included as an event were analysed separately (<LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK>; <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>), this finding was confirmed. In the study which did not include secondary malignant disease as an event, no significant statistical difference in event-free survival between the treatment groups was identified (<LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>). However, the direction of the result of this study was the same as the overall result of all trials. The results of the meta-analysis of event-free survival did not change when additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> were included in the analysis.</P>
<P>The individual studies also reported three- or five-year overall survival. In all three studies (including the additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>) no significant statistical difference between the treatment groups was identified. Our original meta-analysis using the complete follow-up period showed a significant statistical difference in overall survival in favour of the myeloablative therapy group (HR 0.74, 95% CI 0.57 to 0.98, P = 0.04; 2 studies, 360 patients). However, when additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> was included in the meta-analysis the overall result was no longer statistically significant (HR 0.86, 95% CI 0.73 to 1.01, P = 0.43; 3 studies, 739 patients). A possible explanation could be the mortality caused by different late effects (e.g. as described by <LINK REF="REF-Mertens-2001" TYPE="REFERENCE">Mertens 2001</LINK>; <LINK REF="REF-Reulen-2010" TYPE="REFERENCE">Reulen 2010</LINK>). Another possible explanation could be that treatment options for progressive disease or relapse in patients who received myeloablative therapy are more limited than in patients who received conventional therapy or no further treatment. However, more data are needed for a definitive conclusion.</P>
<P>For two evaluated adverse effects (toxicity grade three or higher) it was possible to perform a meta-analysis. No significant statistical differences in secondary malignant disease or treatment-related death were identified between the treatment groups (both with the original data and with the inclusion of additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>). While unexplained heterogeneity was detected in the original analysis of treatment-related death, this was not the case when additional follow-up data were included. Serious infections, sepsis, renal effects, interstitial pneumonitis and veno-occlusive disease were only evaluated in the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> study. There was a significantly higher incidence of renal effects, interstitial pneumonitis and veno-occlusive disease in the myeloablative therapy group, whereas for serious infections and sepsis no significant statistical differences between the treatment groups were identified. These toxicity data did not change with additional follow-up. None of the included studies evaluated quality of life.</P>
<P>In the individual studies different subgroups were evaluated, but the results were not univocal in all studies. As a result, no definitive conclusions can be made regarding the effect of myeloablative therapy or conventional treatment in the different subgroups.</P>
<P>In this review we performed intention-to-treat (ITT) analyses, since they provide the most realistic and unbiased answer to the question of clinical effectiveness (<LINK REF="REF-Lachin-2000" TYPE="REFERENCE">Lachin 2000</LINK>; <LINK REF="REF-Lee-1991" TYPE="REFERENCE">Lee 1991</LINK>). However, for treatment-related death it was not possible to perform an ITT analysis using the <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> data and we therefore performed an as-treated analysis.</P>
<P>'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. The reason that some studies did not identify a significant statistical difference between study groups could be the fact that the number of patients included in these studies was too small to detect a difference between the treatment groups (i.e. low power). Furthermore, the length of follow-up could have been too short to detect a significant difference between the treatment groups.</P>
<P>The risk of bias in the included studies was difficult to assess due to a lack of reporting. As a result, the presence of selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias could not be ruled out. However, at the moment this is the best available evidence from RCTs comparing the efficacy of high-dose chemotherapy and autologous haematopoietic stem cell rescue with conventional therapy in patients diagnosed with high-risk neuroblastoma. With regard to performance bias, it should be noted that due to the nature of the interventions, blinding of care providers and patients was virtually impossible.</P>
<P>The results of myeloablative therapy must be viewed in the context of the different treatment regimens used in the included studies. The included studies differed in terms of the preceding therapy (e.g. induction chemotherapy, surgery and radiotherapy), the myeloablative regimen with or without total body irradiation, the stem cells (e.g. whether purging was used or not, and the origin of the stem cells, i.e. bone marrow or peripheral blood) and the presence and type of consolidation chemotherapy. As a result, in this systematic review we can only provide conclusions on the concept of myeloablative treatment versus conventional or no further treatment. We cannot make conclusions with regard to specific versions of these treatments. However, the concept seems to work in terms of event-free survival, both for all randomised patients treated with myeloablative therapy and for specific subgroups. For overall survival there is currently no evidence of effect. No definitive conclusions can be made regarding adverse effects and quality of life.</P>
<P>We are awaiting the full text publication of the study published as a conference abstract (<LINK REF="STD-Hero-2010" TYPE="STUDY">Hero 2010</LINK>), which presented additional follow-up data from the <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> study. <LINK REF="STD-Hero-2010" TYPE="STUDY">Hero 2010</LINK> reported that myeloablative therapy proved to be effective with respect to long-term outcome, but is complicated by acute and long-term toxicity. However, as it is known that information provided in conference abstracts is often substantially different from information provided in subsequent full text publications (<LINK REF="REF-Yoon-2012" TYPE="REFERENCE">Yoon 2012</LINK>), these results were not included in the analyses of this systematic review.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-09-29 14:00:22 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-09-29 14:00:22 +0200" MODIFIED_BY="[Empty name]">
<P>Our original meta-analyses of both event-free and overall survival showed a significant statistical difference in favour of myeloablative therapy. However, when additional follow-up data from <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK> were included in the meta-analyses the difference in event-free survival remained statistically significant, but the difference in overall survival was no longer statistically significant. A possible explanation could be that treatment options for progressive disease or relapse in patients who received myeloablative therapy are more limited than in patients who received conventional therapy or no further treatment. Another possible explanation could be the mortality caused by different late effects. Nonetheless, more data are needed for a definitive conclusion. Data on adverse effects were very limited, but significantly more events in the myeloablative therapy group were identified for renal effects, interstitial pneumonitis and veno-occlusive disease. The fact that no significant differences in the occurrence of other adverse effects between treatment groups were identified could be the result of low power or too short a follow-up period. No information on quality of life was provided. No definitive conclusions regarding the effect of myeloablative therapy or conventional treatment in different subgroups can be made.</P>
<P>It should be kept in mind that recently the age cut-off for high-risk disease was changed from one year to 18 months. As a result it is possible that patients with what is now classified as intermediate-risk disease were included in the high-risk groups. Consequently the relevance of the results of these studies to the current practice can be questioned. Survival rates may be over estimated due to the inclusion of patients with intermediate-risk disease.</P>
<P>Based on the currently available evidence, we cannot make recommendations for the use of high-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma in clinical practice. This systematic review only allows a conclusion on the concept of myeloablative treatment; no conclusions regarding the best treatment strategy can be made.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-09-29 13:38:23 +0200" MODIFIED_BY="[Empty name]">
<P>Future trials on the use of high-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma should focus on identifying the optimal induction therapy and myeloablative regimen, with regard to survival, (late) adverse effects and quality of life. The best study design to answer these questions is a randomised controlled trial (RCT). RCTs should be performed in homogeneous study populations (e.g. stage of disease) and have a long-term follow up. Different risk groups, using the most recent definitions, should be taken into account. The number of included patients should be sufficient to obtain the power needed for the results to be reliable.</P>
<P>Also, it will be very interesting to examine additional data from the RCTs already performed. We are awaiting the full text publication of additional follow-up data from the <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> study. The performance of an individual patient data analysis including only patients that are classified as high-risk according to the latest definition is another possibility to assess the efficacy of high-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-07-14 14:20:38 +0200" MODIFIED_BY="[Empty name]">
<P>Leontien Kremer and Elvira van Dalen, the Co-ordinating Editors of the Childhood Cancer Group, are both co-authors of this review and therefore they could not act as Co-ordinating Editor for this review. Marianne van de Wetering (Department of Paediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands) was willing to take on this task, for which we would like to thank her. Huib Caron was a co-author of the protocol for this systematic review, the original version and the first update and we thank him for his valuable input. Also, we would like to thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for running the search strategy in the different databases and providing us with the titles and abstracts of the searches, Marcello DiNisio for translating an Italian article and, the Foundation of Paediatric Cancer Research (SKK), the Netherlands and Stichting Kinderen Kankervrij (KIKA), the Netherlands, for the financial support which made it possible to perform this systematic review. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA). For survival analyses, the hazard ratio and associated statistics were calculated using an Excel spreadsheet developed by Matthew Sydes and Jayne Tierney of the MRC Clinical Trials Unit, London, the United Kingdom.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-09-29 13:38:35 +0200" MODIFIED_BY="[Empty name]">
<P>Bilgehan Yalçin: none known.<BR/>Leontien CM Kremer: none known,<BR/>Elvira C van Dalen: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-09-29 13:38:25 +0200" MODIFIED_BY="[Empty name]">
<P>Bilgehan Yalçin designed the study and wrote the protocol. He identified studies meeting the inclusion criteria. He searched for unpublished and ongoing studies. He performed the data extraction and risk of bias assessment of the included studies. He contributed to the interpretation of the results. He critically reviewed the review.</P>
<P>Leontien CM Kremer designed the study and critically reviewed the protocol. She contributed to the interpretation of the results. She critically reviewed the review.</P>
<P>Elvira C van Dalen designed the study and wrote the protocol. She developed the search strategy. She identified the studies meeting the inclusion criteria. She searched for unpublished and ongoing studies. She performed the data extraction and risk of bias assessment of the included studies. She analysed the data and interpreted the results. She wrote and revised the review.</P>
<P>All authors approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-14 14:20:50 +0200" MODIFIED_BY="[Empty name]">
<P>For the first update of this review we extended the search strategy as described in the protocol: we also included the conference proceedings of the American Society of Clinical Oncology (ASCO).</P>
<P>For the second update we used the most recent recommendations of the Childhood Cancer Group for the assessment of risk of bias in the included studies. All RCTs were scored using the new 'risk of bias' items. Also, since performing the original review and the first update of this review, the Childhood Cancer Group has adjusted some of its recommendations regarding analyses: when for a particular outcome only one study is available and there are no events in one of the treatment groups, it is impossible to calculate an adequate risk ratio using the RevMan software, instead the Fischer's exact test should be used. We have adjusted this where necessary. Finally, the websites for the ongoing trials registers changed since doing the original review and the first update; we used the new websites to access the registers.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-01 11:28:13 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-07-14 14:22:24 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-07-14 14:22:24 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Berthold--2005" MODIFIED="2009-08-11 13:26:35 +0200" MODIFIED_BY="[Empty name]" NAME="Berthold  2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-11 13:26:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al</AU>
<TI>Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial</TI>
<SO>Lancet Oncology</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>649-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthay-1999" MODIFIED="2015-07-14 14:22:24 +0200" MODIFIED_BY="[Empty name]" NAME="Matthay 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-02-05 10:11:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al</AU>
<TI>Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>7</NO>
<PG>1007-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-13 01:27:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al</AU>
<TI>Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1165-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-14 14:22:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No authors named</AU>
<TI>Erratum</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2014</YR>
<VL>32</VL>
<NO>17</NO>
<PG>1862-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pritchard-2005" MODIFIED="2009-08-12 09:41:05 +0200" MODIFIED_BY="[Empty name]" NAME="Pritchard 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-12 09:41:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR</AU>
<TI>High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2005</YR>
<VL>44</VL>
<PG>348-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-04-12 09:10:07 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adkins-2004" MODIFIED="2009-08-13 09:25:31 +0200" MODIFIED_BY="[Empty name]" NAME="Adkins 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-13 09:25:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM</AU>
<TI>Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>931-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berthold-1990" MODIFIED="2009-08-13 13:02:54 +0200" MODIFIED_BY="[Empty name]" NAME="Berthold 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-08-13 13:02:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berthold F, Burdach S, Kremens B, Lampert F, Niethammer D, Riehm H, et al</AU>
<TI>The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience</TI>
<SO>Klinische Pädiatrie</SO>
<YR>1990</YR>
<VL>202</VL>
<PG>262-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castel-2001" MODIFIED="2009-08-13 09:36:11 +0200" MODIFIED_BY="[Empty name]" NAME="Castel 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-08-13 09:36:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castel V, Cañete A, Navarro S, García-Miguel P, Melero C, Acha T, et al</AU>
<TI>Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>537-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castel-2002" MODIFIED="2009-08-13 09:34:12 +0200" MODIFIED_BY="[Empty name]" NAME="Castel 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-13 09:34:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, et al</AU>
<TI>The role of surgery in stage IV neuroblastoma</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2002</YR>
<VL>37</VL>
<PG>1574-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dini-1989" MODIFIED="2009-08-13 13:04:48 +0200" MODIFIED_BY="[Empty name]" NAME="Dini 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-08-13 13:04:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dini G, Philip T, Hartmann O, Pinkerton R, Chauvin F, Garaventa A, et al</AU>
<TI>Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>Suppl 4</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dini-1991a" MODIFIED="2010-04-12 09:08:17 +0200" MODIFIED_BY="[Empty name]" NAME="Dini 1991a" YEAR="">
<REFERENCE MODIFIED="2010-04-12 09:08:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dini G, Lanino E, Garaventa A, Paolucci P, Amici A, Locatelli F, et al</AU>
<TI>Unpurged ABMT for neuroblastoma: AIEOP-BMT experience</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dini-1991b" MODIFIED="2010-04-12 09:08:38 +0200" MODIFIED_BY="[Empty name]" NAME="Dini 1991b" YEAR="">
<REFERENCE MODIFIED="2010-04-12 09:08:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dini G, Lanino E, Garaventa A, Paolucci P, Amici A, Locatelli F, et al</AU>
<TI>Unpurged autologous bone marrow transplantation for neuroblastoma: the AIEOP-BMT group experience</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>Suppl 3</NO>
<PG>109-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garaventa-1993" MODIFIED="2009-08-13 12:45:31 +0200" MODIFIED_BY="[Empty name]" NAME="Garaventa 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-08-13 12:45:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garaventa A, Ladenstein R, Chauvin F, Lanino E, Philip I, Corciulo P, et al</AU>
<TI>High-dose chemotherapy with autologous bone marrow rescue in advanced stage IV neuroblastoma</TI>
<SO>European Journal of Cancer</SO>
<YR>1993</YR>
<VL>29A</VL>
<PG>487-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas_x002d_Kogan-2003" MODIFIED="2009-08-13 09:30:24 +0200" MODIFIED_BY="[Empty name]" NAME="Haas-Kogan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-13 09:30:22 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, et al</AU>
<TI>Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2003</YR>
<VL>56</VL>
<PG>28-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-1985" MODIFIED="2009-08-13 13:11:42 +0200" MODIFIED_BY="[Empty name]" NAME="Hartmann 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-08-13 13:11:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann O, Zucker JM, Pinkerton R, Philip T, Beaujean F, Bernard JL, et al</AU>
<TI>Metastatic neuroblastoma in children older than one year old at diagnosis. Treatment with intensive chemo-radiotherapy and autologous bone marrow transplant</TI>
<SO>Revue Française de Transfusion et Immuno-Hématologie</SO>
<YR>1985</YR>
<VL>28</VL>
<PG>539-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaneko-1999" MODIFIED="2009-10-06 10:50:23 +0200" MODIFIED_BY="[Empty name]" NAME="Kaneko 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-10-06 10:50:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaneko M, Tsuchida Y, Uchino J, Takeda T, Iwafuchi M, Ohnuma N, et al</AU>
<TI>Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>1999</YR>
<VL>21</VL>
<PG>190-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klingebiel-1994" MODIFIED="2009-08-13 12:41:47 +0200" MODIFIED_BY="[Empty name]" NAME="Klingebiel 1994" YEAR="1995">
<REFERENCE MODIFIED="2009-08-13 12:41:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klingebiel T, Handgretinger R, Herter M, Lang P, Dopfer R, Scheel-Walter H, et al</AU>
<TI>Peripheral stem cell transplantation in neuroblastoma stage 4 with the use of [131I-m]IBG</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1994</YR>
<VL>385</VL>
<PG>309-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladenstein-1991" MODIFIED="2009-08-13 12:53:28 +0200" MODIFIED_BY="[Empty name]" NAME="Ladenstein 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-13 12:53:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladenstein R, Lasset C, Bouffet E, Brunat-Mentigny M, Biron P, Philip I, et al</AU>
<TI>A single center experience with bone marrow transplantation for high risk neuroblastoma</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladenstein-1996" MODIFIED="2010-04-12 09:09:12 +0200" MODIFIED_BY="[Empty name]" NAME="Ladenstein 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-12 09:09:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladenstein R, Ambros PF, Urban C, Ambros IM, Fink FM, Zoubek A, et al</AU>
<TI>Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study</TI>
<SO>Klinische Pädiatrie</SO>
<YR>1996</YR>
<VL>208</VL>
<PG>210-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madon-1985" MODIFIED="2010-04-12 09:09:27 +0200" MODIFIED_BY="[Empty name]" NAME="Madon 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-04-12 09:09:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madon E, Pastore G, Cordero di Montezemolo L, Brach del Prever A, Lanino E</AU>
<TI>Italian multicenter experience in the treatment of neuroblastoma and soft tissue sarcoma</TI>
<SO>Minerva Pediatrica</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>603-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthay-1995" MODIFIED="2009-08-13 12:39:28 +0200" MODIFIED_BY="[Empty name]" NAME="Matthay 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-13 12:39:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, et al</AU>
<TI>Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>572-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthay-1996" MODIFIED="2009-08-13 09:48:03 +0200" MODIFIED_BY="[Empty name]" NAME="Matthay 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-13 09:48:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK</AU>
<TI>Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>Suppl 3</NO>
<PG>S21-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthay-1998" MODIFIED="2009-08-13 09:46:14 +0200" MODIFIED_BY="[Empty name]" NAME="Matthay 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-13 09:46:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al</AU>
<TI>Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1256-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mugishima-1999" MODIFIED="2010-04-12 09:10:07 +0200" MODIFIED_BY="[Empty name]" NAME="Mugishima 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-04-12 09:10:07 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mugishima H</AU>
<TI>High-dose chemotherapy and hematopoietic stem cell transplant in the treatment of advanced neuroblastoma</TI>
<SO>Gan To Kagaku Ryoho</SO>
<YR>1999</YR>
<VL>26</VL>
<PG>1056-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohnuma-1995" MODIFIED="2009-08-13 12:37:06 +0200" MODIFIED_BY="[Empty name]" NAME="Ohnuma 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-13 12:37:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohnuma N, Takahashi H, Kaneko M, Uchino J, Takeda T, Iwafuchi M, et al</AU>
<TI>Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>1995</YR>
<VL>24</VL>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olgun-2008" MODIFIED="2009-10-06 11:01:09 +0200" MODIFIED_BY="[Empty name]" NAME="Olgun 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-10-06 11:01:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Olgun N, Gunes D, Aksoylar S, Varan A, Erbay A, Hazar V, et al</AU>
<TI>The Turkish Pediatric Oncology Group Neuroblastoma 2003 (TPOG-NB-2003): treatment results of the high risk group (abstract D110)</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2008</YR>
<PG>140</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paolucci-1989" MODIFIED="2009-08-13 13:06:38 +0200" MODIFIED_BY="[Empty name]" NAME="Paolucci 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-08-13 13:06:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paolucci P, Mancini AF, Rosito P, Vecchi V, Vivarelli F, Granchi D, et al</AU>
<TI>Intensification of induction prior to intensification of consolidation and bone marrow rescue in disseminated neuroblastoma</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>Suppl 4</NO>
<PG>151-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philip-1991" MODIFIED="2009-08-13 12:51:10 +0200" MODIFIED_BY="[Empty name]" NAME="Philip 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-13 12:51:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Philip T, Zucker JM, Bernard JL, Lutz P, Bordigoni P, Plouvier E, et al</AU>
<TI>The LMCE1 unselected group of stage IV neuroblastoma revisited with a median follow up of 59 months after ABMT</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1991</YR>
<VL>366</VL>
<PG>517-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinkerton-1991" MODIFIED="2009-08-13 13:00:42 +0200" MODIFIED_BY="[Empty name]" NAME="Pinkerton 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-13 13:00:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinkerton CR</AU>
<TI>ENSG 1-randomised study of high-dose melphalan in neuroblastoma</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>Suppl 3</NO>
<PG>112-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saarinen-1996" MODIFIED="2009-08-13 10:52:39 +0200" MODIFIED_BY="[Empty name]" NAME="Saarinen 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-13 10:52:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saarinen UM, Wikström S, Mäkipernaa A, Lanning M, Perkkiö M, Hovi L, et al</AU>
<TI>In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>2791-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawaguchi-1989" MODIFIED="2010-04-12 09:09:49 +0200" MODIFIED_BY="[Empty name]" NAME="Sawaguchi 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-04-12 09:09:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawaguchi S, Kaneko M, Nakajo T, Sawada T, Takahashi H, Tsuchida Y</AU>
<TI>A preliminary treatment report of the Study Group of Japan for Advanced Neuroblastoma</TI>
<SO>Nippon Gan Chiryo Gakkai Shi</SO>
<YR>1989</YR>
<VL>24</VL>
<PG>1020-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawaguchi-1990" MODIFIED="2009-08-11 15:02:49 +0200" MODIFIED_BY="[Empty name]" NAME="Sawaguchi 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-08-11 15:02:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawaguchi S, Kaneko M, Uchino J, Takeda T, Iwafuchi M, Matsuyama S, et al</AU>
<TI>Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan</TI>
<SO>Cancer</SO>
<YR>1990</YR>
<VL>66</VL>
<PG>1879-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2005" MODIFIED="2009-08-13 09:27:43 +0200" MODIFIED_BY="[Empty name]" NAME="Schmidt 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-13 09:27:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, et al</AU>
<TI>Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>6474-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seeger-1991" MODIFIED="2009-08-13 12:49:14 +0200" MODIFIED_BY="[Empty name]" NAME="Seeger 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-13 12:49:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, et al</AU>
<TI>Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1991</YR>
<VL>366</VL>
<PG>527-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seeger-2000" MODIFIED="2009-08-13 09:38:02 +0200" MODIFIED_BY="[Empty name]" NAME="Seeger 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-08-13 09:38:02 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK</AU>
<TI>Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<PG>4067-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuster-1991" MODIFIED="2009-08-13 12:47:13 +0200" MODIFIED_BY="[Empty name]" NAME="Shuster 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-13 12:47:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shuster JJ, Cantor AB, McWilliams N, Pole JG, Castleberry RP, Marcus R, et al</AU>
<TI>The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>1045-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stram-1994" MODIFIED="2009-08-13 12:43:25 +0200" MODIFIED_BY="[Empty name]" NAME="Stram 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-08-13 12:43:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stram DO, Matthay KK, O'Leary M, Reynolds CP, Seeger RC</AU>
<TI>Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma</TI>
<SO>Progress in Clinical and Biological Research</SO>
<YR>1994</YR>
<VL>385</VL>
<PG>287-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stram-1996" MODIFIED="2009-08-13 10:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Stram 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-08-13 10:55:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, et al</AU>
<TI>Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>2417-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zucker-1991" MODIFIED="2009-08-13 12:54:59 +0200" MODIFIED_BY="[Empty name]" NAME="Zucker 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-13 12:54:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zucker JM, Philip T, Bernard JL, Michon J, Bouffet E, Gentet JC, et al</AU>
<TI>Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-02-05 10:11:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hero-2010" MODIFIED="2013-02-05 10:11:57 +0100" MODIFIED_BY="[Empty name]" NAME="Hero 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-02-05 10:11:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hero B, Thorsten S, Dillo D, Kremens B, Grigull L, Scheel-Walter HG, et al</AU>
<TI>Long term outcome: the price of treatment for surviving high-risk neuroblastoma</TI>
<SO>Advances in Neuroblastoma Research Association</SO>
<YR>2010</YR>
<PG>105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-01 11:28:13 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-01 11:28:13 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aydin-2009" MODIFIED="2010-02-24 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Aydin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Aydin GB, Kutluk MT, Yalçin B, Büyükpamukçu M, Kale G, Varan A, et al</AU>
<TI>Neuroblastoma in Turkish children: experience of a single center</TI>
<SO>Journal of Pediatric Hematology and Oncology</SO>
<YR>2009</YR>
<VL>31</VL>
<PG>471-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bollard-2006" NAME="Bollard 2006" TYPE="BOOK_SECTION">
<AU>Bollard CM, Krance RA, Heslop HE</AU>
<TI>Hematopoietic stem cell transplantation in pediatric oncology</TI>
<SO>Principles and practice of pediatric oncology</SO>
<YR>2006</YR>
<PG>476-500</PG>
<EN>5th</EN>
<ED>Pizzo PA, Poplack DG</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brodeur-1988" MODIFIED="2010-02-24 10:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Brodeur 1988" TYPE="JOURNAL_ARTICLE">
<AU>Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al</AU>
<TI>International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>1874-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brodeur-1993" MODIFIED="2010-02-24 10:55:51 +0100" MODIFIED_BY="[Empty name]" NAME="Brodeur 1993" TYPE="JOURNAL_ARTICLE">
<AU>Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al</AU>
<TI>Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>1466-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brodeur-2006" MODIFIED="2010-04-12 09:12:21 +0200" MODIFIED_BY="[Empty name]" NAME="Brodeur 2006" TYPE="BOOK_SECTION">
<AU>Brodeur GM, Maris JM</AU>
<TI>Neuroblastoma</TI>
<SO>Principles and practice of pediatric oncology</SO>
<YR>2006</YR>
<PG>933-70</PG>
<EN>5th</EN>
<ED>Pizzo PA, Poplack DG</ED>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burchill-2004" NAME="Burchill 2004" TYPE="JOURNAL_ARTICLE">
<AU>Burchill SA</AU>
<TI>Micrometastases in neuroblastoma: are they clinically important?</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>2004</YR>
<VL>57</VL>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castel-1995" NAME="Castel 1995" TYPE="JOURNAL_ARTICLE">
<AU>Castel V, García-Miguel P, Melero C, Navajas A, Navarro S, Molina J, et al. On behalf of the Spanish Neuroblastoma Study Group</AU>
<TI>The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) Studies</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>642-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-1991" NAME="Cheung 1991" TYPE="JOURNAL_ARTICLE">
<AU>Cheung NK, Heller G</AU>
<TI>Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>1050-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohn-1997" NAME="Cohn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cohn SL, Moss TJ, Hoover M, Katzenstein HM, Haut PR, Morgan ER, et al</AU>
<TI>Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1997</YR>
<VL>20</VL>
<PG>543-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohn-2009" MODIFIED="2013-08-19 11:32:48 +0200" MODIFIED_BY="[Empty name]" NAME="Cohn 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al</AU>
<TI>The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>2</NO>
<PG>289-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Bernardi-2003" NAME="De Bernardi 2003" TYPE="JOURNAL_ARTICLE">
<AU>De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, di Montezemolo LC, et al</AU>
<TI>Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>1592-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2015-09-29 13:39:45 +0200" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Caro-1994" NAME="Di Caro 1994" TYPE="JOURNAL_ARTICLE">
<AU>Di Caro A, Bostrom B, Moss TJ, Neglia J, Ramsay NK, Smith J, et al</AU>
<TI>Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma</TI>
<SO>American Journal of Pediatric Hematology/Oncology</SO>
<YR>1994</YR>
<VL>16</VL>
<PG>200-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1971" MODIFIED="2013-08-19 11:34:22 +0200" MODIFIED_BY="[Empty name]" NAME="Evans 1971" TYPE="JOURNAL_ARTICLE">
<AU>Evans AE, D'Angio GJ, Randolph J</AU>
<TI>A proposed staging for children with neuroblastoma. Children's cancer study group A</TI>
<SO>Cancer</SO>
<YR>1971</YR>
<VL>27</VL>
<PG>374-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldsby-2004" MODIFIED="2013-08-19 11:35:23 +0200" MODIFIED_BY="John K MacDonald" NAME="Goldsby 2004" TYPE="JOURNAL_ARTICLE">
<AU>Goldsby RE, Matthay KK</AU>
<TI>Neuroblastoma: evolving therapies for a disease with many faces</TI>
<SO>Paediatric Drugs</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>107-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-09-29 13:40:30 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2010-04-12 09:17:18 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2006. John Wiley &amp; Sons Ltd, Chichester (UK)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-04-12 09:12:50 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-09-29 13:41:11 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<YR>Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaneko-2002" NAME="Kaneko 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, et al</AU>
<TI>Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2002</YR>
<VL>24</VL>
<PG>613-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keshelava-1998" NAME="Keshelava 1998" TYPE="JOURNAL_ARTICLE">
<AU>Keshelava N, Seeger RC, Groshen S, Reynolds CP</AU>
<TI>Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy</TI>
<SO>Cancer Research</SO>
<YR>1998</YR>
<VL>58</VL>
<PG>5396-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kremer-2014" MODIFIED="2015-07-14 14:24:17 +0200" MODIFIED_BY="[Empty name]" NAME="Kremer 2014" TYPE="OTHER">
<AU>Kremer LCM, Leclercq E, van Dalen EC</AU>
<TI>Cochrane Childhood Cancer Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2014, Issue 5. Art. No.: CHILDCA</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kushner-2004" NAME="Kushner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK</AU>
<TI>Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>4888-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lachin-2000" MODIFIED="2009-09-30 12:33:59 +0200" MODIFIED_BY="[Empty name]" NAME="Lachin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lachin JM</AU>
<TI>Statistical considerations in the intent-to-treat principle</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2000</YR>
<VL>21</VL>
<PG>167-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ladenstein-1994" NAME="Ladenstein 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ladenstein R, Lasset C, Hartmann O, Klingebiel T, Bouffet E, Gadner H, et al</AU>
<TI>Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ladenstein-2004" MODIFIED="2010-04-12 09:13:45 +0200" MODIFIED_BY="[Empty name]" NAME="Ladenstein 2004" TYPE="BOOK_SECTION">
<AU>Ladenstein R, Hartmann O, Koscielnak E, Philip T</AU>
<TI>Megatherapy with stem cell rescue in solid tumours</TI>
<SO>Pediatric Oncology</SO>
<YR>2004</YR>
<PG>538-569</PG>
<EN>3rd</EN>
<ED>Pinkerton R, Plowman PN, Pieters R</ED>
<PB>Arnold Publishers</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laprie-2004" NAME="Laprie 2004" TYPE="JOURNAL_ARTICLE">
<AU>Laprie A, Michon J, Hartmann O, Munzer C, Leclair MD, Coze C, et al; Neuroblastoma Study Group of the French Society of Pediatric Oncology</AU>
<TI>High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification</TI>
<SO>Cancer</SO>
<YR>2004</YR>
<VL>101</VL>
<PG>1081-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-1991" MODIFIED="2009-09-30 12:35:47 +0200" MODIFIED_BY="[Empty name]" NAME="Lee 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB</AU>
<TI>Analysis of clinical trials by treatment actually received: is it really an option?</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>1595-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2015-10-01 11:28:13 +0200" MODIFIED_BY="Denise M Mitchell" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maris-2005" NAME="Maris 2005" TYPE="JOURNAL_ARTICLE">
<AU>Maris JM</AU>
<TI>The biologic basis for neuroblastoma heterogeneity and risk stratification</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>7-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maris-2007" MODIFIED="2013-02-05 10:15:09 +0100" MODIFIED_BY="[Empty name]" NAME="Maris 2007" TYPE="JOURNAL_ARTICLE">
<AU>Maris JM, Hogarty MD, Bagatell R, Cohn SL</AU>
<TI>Neuroblastoma</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9579</NO>
<PG>2106-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matthay-1993" NAME="Matthay 1993" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC</AU>
<TI>Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>2226-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matthay-2009" MODIFIED="2009-09-30 15:13:44 +0200" MODIFIED_BY="[Empty name]" NAME="Matthay 2009" TYPE="JOURNAL_ARTICLE">
<AU>Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al</AU>
<TI>Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>1007-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mertens-2001" MODIFIED="2013-02-05 10:15:19 +0100" MODIFIED_BY="[Empty name]" NAME="Mertens 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, et al</AU>
<TI>Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>3163-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2009-09-08 12:17:45 +0200" MODIFIED_BY="[Empty name]" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peinemann-2015a" MODIFIED="2015-07-14 14:23:56 +0200" MODIFIED_BY="[Empty name]" NAME="Peinemann 2015a" TYPE="COCHRANE_REVIEW">
<AU>Peinemann F, Tushabe DA, van Dalen EC, Berthold F</AU>
<TI>Rapid COJEC versus standard induction therapies for high-risk neuroblastoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-06-24 11:34:30 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 11:34:30 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010774.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peinemann-2015b" MODIFIED="2015-07-14 14:24:01 +0200" MODIFIED_BY="[Empty name]" NAME="Peinemann 2015b" TYPE="COCHRANE_REVIEW">
<AU>Peinemann F, van Dalen EC, Tushabe DA, Berthold F</AU>
<TI>Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-06-24 11:32:40 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 11:32:40 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010685.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Philip-1997" NAME="Philip 1997" TYPE="JOURNAL_ARTICLE">
<AU>Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, et al</AU>
<TI>1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party</TI>
<SO>European Journal of Cancer</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>2130-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pritchard-1995" MODIFIED="2010-04-12 09:16:10 +0200" MODIFIED_BY="[Empty name]" NAME="Pritchard 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pritchard J</AU>
<TI>"Megatherapy" for advanced neuroblastoma - rationale and role</TI>
<SO>European Journal of Cancer</SO>
<YR>1995</YR>
<VL>31A</VL>
<PG>134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reulen-2010" MODIFIED="2013-02-05 10:14:53 +0100" MODIFIED_BY="[Empty name]" NAME="Reulen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al</AU>
<TI>Long-term cause-specific mortality among survivors of childhood cancer</TI>
<SO>Journal of American Medical Association</SO>
<YR>2010</YR>
<VL>304</VL>
<PG>172-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-09-29 13:43:23 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-2001" NAME="Reynolds 2001" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds CP, Seeger RC</AU>
<TI>Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma</TI>
<SO>Journal of Pediatric Hematology/Oncology</SO>
<YR>2001</YR>
<VL>23</VL>
<PG>150-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-2004" MODIFIED="2010-04-12 09:15:16 +0200" MODIFIED_BY="[Empty name]" NAME="Reynolds 2004" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds CP</AU>
<TI>Detection and treatment of minimal residual disease in high-risk neuroblastoma</TI>
<SO>Pediatric Transplantation</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>Suppl 5</NO>
<PG>56-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shimada-1984" MODIFIED="2010-02-24 12:00:32 +0100" MODIFIED_BY="[Empty name]" NAME="Shimada 1984" TYPE="JOURNAL_ARTICLE">
<AU>Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, et al</AU>
<TI>Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1984</YR>
<VL>73</VL>
<PG>405-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-09-29 13:43:44 +0200" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). <I>Cochrane Handbook for Systematic Reviews of Intervention.</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trahair-2007" MODIFIED="2013-02-05 10:14:37 +0100" MODIFIED_BY="[Empty name]" NAME="Trahair 2007" TYPE="JOURNAL_ARTICLE">
<AU>Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, et al</AU>
<TI>Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2007</YR>
<VL>40</VL>
<NO>8</NO>
<PG>741-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verdeguer-2004" NAME="Verdeguer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Verdeguer A, Munoz A, Canete A, Pardo N, Martinez A, Donat J, et al</AU>
<TI>Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon)</TI>
<SO>Pediatric Hematology and Oncology</SO>
<YR>2004</YR>
<VL>21</VL>
<PG>495-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinstein-2003" NAME="Weinstein 2003" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein JL, Katzenstein HM, Cohn SL</AU>
<TI>Advances in the diagnosis and treatment of neuroblastoma</TI>
<SO>The Oncologist</SO>
<YR>2003</YR>
<VL>8</VL>
<PG>278-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoon-2012" MODIFIED="2013-02-05 10:13:31 +0100" MODIFIED_BY="[Empty name]" NAME="Yoon 2012" TYPE="JOURNAL_ARTICLE">
<AU>Yoon U, Knobloch K</AU>
<TI>Assessment of reporting quality of conference abstracts in sports injury prevention according to CONSORT and STROBE criteria and their subsequent publication rate as full papers</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2010" MODIFIED="2013-04-14 11:55:56 +0200" MODIFIED_BY="[Empty name]" NAME="Yu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al</AU>
<TI>Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>14</NO>
<PG>1324-34</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-14 14:23:40 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Yal_x00e7_in-2006" MODIFIED="2012-11-07 14:23:04 +0100" MODIFIED_BY="[Empty name]" NAME="Yalçin 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Yalçin B, Kremer LC, Caron HN, van Dalen EC</AU>
<TI>High dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-11-07 14:22:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-11-07 14:22:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yal_x00e7_in-2010" MODIFIED="2012-11-07 14:19:45 +0100" MODIFIED_BY="[Empty name]" NAME="Yalçin 2010" TYPE="COCHRANE_REVIEW">
<AU>Yalçin B, Kremer LC, Caron HN, van Dalen EC</AU>
<TI>High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2012-11-07 14:19:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-11-07 14:19:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006301.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yal_x00e7_in-2013" MODIFIED="2015-07-14 14:23:40 +0200" MODIFIED_BY="[Empty name]" NAME="Yalçin 2013" TYPE="COCHRANE_REVIEW">
<AU>Yalçin B, Kremer LCM, Caron HN, van Dalen EC</AU>
<TI>High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2015-06-24 10:41:58 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-24 10:41:58 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006301.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-09-29 14:01:18 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-09-29 13:38:57 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-09-29 13:38:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berthold--2005">
<CHAR_METHODS MODIFIED="2015-09-29 13:38:37 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed centrally by computer-generated sequence with a block size of 8. The stratification criteria were MYCN alone (amplified vs not amplified vs unknown), concentration of serum LDH at diagnosis (raised vs not raised vs unknown), and age (1 to &lt; 2 years vs <U>&gt;</U> 2 years at diagnosis).</P>
<P>Randomisation was performed at a median of 39 days (range 7 to 224 days) after diagnosis. Patients were randomised to myeloablative therapy or conventional chemotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-19 11:26:13 +0200" MODIFIED_BY="[Empty name]">
<P>295 children with high-risk neuroblastoma.</P>
<P>
<I>High-risk neuroblastoma was defined as</I>: stage IV disease in patients older than 1 year or as MYCN-amplified tumours in patients with stage I, II, III or IV-S disease or with stage IV disease and aged younger than 1 year. Staging was done in accordance with the International Neuroblastoma Staging System criteria (<LINK REF="REF-Brodeur-1993" TYPE="REFERENCE">Brodeur 1993</LINK>).</P>
<P>
<I>Age</I>: 22 patients &lt; 1 year and 273 patients &gt; 1 year</P>
<P>
<I>Sex:</I> not reported</P>
<P>
<I>Stage of disease</I>: I (n = 2), II (n = 6), III (n = 19), IV-S (n = 5) and IV (n = 263)</P>
<P>
<I>Primary disease or recurrence</I>: not reported</P>
<P>
<I>Histology</I>: not reported</P>
<P>
<I>Bone metastases</I>: yes n = 179, no n = 116 (including 84 stage IV patients)</P>
<P>
<I>Immunocytologic analysis of bone marrow at diagnosis</I>: not reported</P>
<P>
<I>MYCN amplification</I>: yes n = 114, no n = 176, unclear n = 5</P>
<P>
<I>Serum LDH level </I>(cut-off values not mentioned): raised n = 262, not raised n = 29, not reported n = 4</P>
<P>
<I>Induction regimen</I>:</P>
<P>Data for all randomised patients were not available; these are data for 212 of the 295 patients. According to protocol, they received 3 N5 cycles with 40 mg/m<SUP>2</SUP> cisplatin a day and 100 mg/m<SUP>2 </SUP>etoposide a day, both given as continuous infusion over 96 hours on days 1 to 4, and 3 mg/m<SUP>2</SUP> vindesine given intravenously over 1 hour on day 1; and 3 N6 cycles with 1.5 mg/m<SUP>2</SUP> vincristine a day given intravenously over 1 hour on days 1 and 8, 200 mg/m<SUP>2</SUP> dacarbazine a day given intravenously over 1 hour on days 1 to 5, 1.5 g/m<SUP>2</SUP> ifosfamide a day given as continuous infusion over 120 hours on days 1 to 5, and 30 mg/m<SUP>2</SUP> doxorubicin a day given intravenously over 4 hours on days 6 and 7. In a pilot setting, 3 patients received cycles with slightly higher doses of etoposide (125 mg/m<SUP>2</SUP> a day given as continuous infusion over 96 hours on days 1 to 4) and a different infusion time for doxorubicin (48 hours continuous infusion instead of 2 infusions of 4 hours each). Actually received cumulative doses were not reported. The N5 and N6 cycles were alternated; the total duration of the induction regimen was 5 to 7 months.</P>
<P>
<I>External radiotherapy</I>:</P>
<P>Patients with contrast medium or MIBG uptake in the primary tumour at the end of induction chemotherapy had local radiotherapy to the primary residual tumour. Data for all randomised patients were not available; these are data for 212 of the 295 patients. Yes (36-40 Gy to residual tumour) n = 24, no n = 188.</P>
<P>
<I>Surgery:</I>
</P>
<P>Timing of surgery varied during induction chemotherapy regimen: at diagnosis or after 2nd, 4th or 6th cycles of chemotherapy.</P>
<P>
<I>Therapeutic MIBG-I<SUP>131:</SUP>
</I>
</P>
<P>Patients with clear uptake of 123-iodine MIBG in metastatic lesions at the end of induction chemotherapy received MIBG therapy. Data for all randomised patients were not available; these are data for 212 of the 295 patients. Yes n = 28.</P>
<P>
<I>Immunotherapy:</I>
</P>
<P>For 1 year was started 4 to 6 weeks after the end of the conventional chemotherapy or after recovery of the haemopoiesis after megatherapy. Six infusion cycles (one cycle every 2 months) of 20 mg/m<SUP>2</SUP> ch14.18 (chimeric monoclonal antibody against GD2) a day given intravenously over 8 to 12 hours on days 1 to 5 of every cycle. Yes n = 146.</P>
<P>
<I>Retinoic acid:</I>
</P>
<P>After November 2002, instead of immunotherapy: 160 mg/m<SUP>2</SUP>/day, oral on days 1 to 14, followed by a break for 14 days, for 6 months. After 3 months&#8217; break, retinoic acid was resumed for another 3 months. Yes n = 35.</P>
<P>
<I>Supportive care:</I>
</P>
<P>Prophylactic antibiotics not reported, growth factors not reported, granulocyte infusions not reported, other: drugs were given to control pain and allergic reactions during immunotherapy (n = not reported).</P>
<P>
<I>Response before randomisation: </I>
</P>
<P>Complete remission or very good partial remission n = 163, partial remission n = 87, stable disease (or mixed remission) n = 13, progressive disease (or death) n = 25, not reported n = 1, not applicable n = 6. Response was assessed by use of the International Neuroblastoma Remission Criteria (<LINK REF="REF-Brodeur-1993" TYPE="REFERENCE">Brodeur 1993</LINK>)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:38:44 +0200" MODIFIED_BY="[Empty name]">
<P>Data for all randomised patients were not available; data were available for 212 of the 295 patients.</P>
<P>
<I>Myeloablative therapy (n = 149):</I>
</P>
<P>According to protocol: melphalan 45 mg/m<SUP>2</SUP> a day given intravenously over 30 minutes on days 8 to 5 before transplantation, etoposide 40 mg/kg a day given intravenously over 4 hours on day 4 before transplantation, carboplatin 500 mg/m<SUP>2</SUP> a day given intravenously over 1 hour on days 4 to 2 before transplantation. Actually received cumulative doses not mentioned. Note: some dose and drug adjustments were made in 6 patients because of hearing loss: 3 received cyclophosphamide instead of carboplatin and 3 received no carboplatin. In 9 children, melphalan was combined with busulfan. Use of total body irradiation was not reported. 
</P>
<P>Source of stem cells: autologous peripheral blood.</P>
<P>Timing of cell harvest: between 2nd and 5th induction regimen.</P>
<P>Timing of stem cell rescue: after 6th induction chemotherapy cycle.</P>
<P>Number of cells infused: 1-2 X 10<SUP>6</SUP>/kg CD 34(+) cells was recommended.</P>
<P>Contamination with tumour cells: not mentioned.</P>
<P>Purging:  yes n = 96, no n = 1, not mentioned n = 13</P>
<P>
<I>Conventional therapy (n = 146):</I>
</P>
<P>According to protocol: 4 N7 cycles: cyclophosphamide, 150 mg/m<SUP>2</SUP> a day, orally, with mesna 50 mg/m<SUP>2</SUP> 3 times a day on days 1 to 8. Actually received cumulative doses not mentioned</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-19 11:26:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Event-free survival </I>(defined as time until disease progression or relapse, a second neoplastic disease, or death from any cause, whichever occurred first, or until the last examination).</P>
<P>
<I>Overall survival</I> (defined as death from any cause or until the last examination if the patient survived).</P>
<P>
<I>Adverse effects</I>, i.e. second malignancies and treatment-related deaths (according to World Health Organization criteria)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-19 11:26:39 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow up not reported (median follow up for all cases alive at the censoring date was 3.57 years (range 1.01 to 7.02))</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:38:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthay-1999">
<CHAR_METHODS MODIFIED="2015-09-29 13:38:48 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed by permuted-block design using strata with and without metastatic disease. Randomisation was performed at week 8, before the 3rd cycle of chemotherapy for patients without disease progression at a median of 60 days after diagnosis. Patients were randomised to myeloablative therapy or conventional chemotherapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-28 11:34:46 +0200" MODIFIED_BY="Denise M Mitchell">
<P>379 children with high-risk neuroblastoma.</P>
<P>
<I>High-risk neuroblastoma was defined as</I>: stage IV neuroblastoma; stage III disease with one or more of the following: amplification of the MYCN oncogene, a serum ferritin level of at least 143 ng per millilitre, and unfavourable histopathological findings; stage II disease with amplification of MYCN (age &gt; 1 year); stage I or II disease with bone metastases before therapy other than surgery; and stage IV disease with MYCN amplification for less than 1 year. Staging was done using the Evans staging criteria (<LINK REF="REF-Evans-1971" TYPE="REFERENCE">Evans 1971</LINK>). Unfavourable histopathological findings were based on the Shimada classification (<LINK REF="REF-Shimada-1984" TYPE="REFERENCE">Shimada 1984</LINK>).</P>
<P>
<I>Age</I>: 9 patients &lt; 1 year and 370 patients &gt; 1 year</P>
<P>
<I>Sex:</I> not reported</P>
<P>
<I>Stage of disease</I>: I (n = 0), II with MYCN amplification (n = 1), III (n = 44), IV-S (n = 0) and IV (n = 334)</P>
<P>
<I>Primary disease or recurrence</I>: all primary disease</P>
<P>
<I>Histology</I>: favourable n = 15, unfavourable n = 248, unclear n = 116</P>
<P>
<I>Bone metastases</I>: yes n = 230, no n = 149 (including 104 stage IV patients)</P>
<P>
<I>Immunocytologic analysis of bone marrow at diagnosis</I>: negative n = 66, positive n = 184, unclear n = 129</P>
<P>
<I>MYCN amplification</I>: yes n = 104, no n = 179, unclear n = 96</P>
<P>
<I>Serum LDH level: </I>not reported</P>
<P>
<I>Induction regimen</I>:</P>
<P>According to protocol all patients received 5 courses at 28-day intervals of cisplatin 60 mg/m<SUP>2 </SUP>on day 0; doxorubicin 30 mg/m<SUP>2 </SUP>on day 2; etoposide 100 mg/m<SUP>2</SUP>on days 2 and 5; cyclophosphamide 1 gr/m<SUP>2 </SUP>on days 3 - 4. Actually received cumulative doses not reported.</P>
<P>
<I>External radiotherapy</I>:</P>
<P>Following induction regimen patients with gross residual disease received surgery and radiotherapy. Number of patients not reported.<BR/>
<I>Surgery:</I>
</P>
<P>Timing of surgery: after cycle 4 of induction chemotherapy.</P>
<P>
<I>Therapeutic MIBG-I<SUP>131:</SUP>
</I>
</P>
<P>No</P>
<P>
<I>Immunotherapy:</I>
</P>
<P>No</P>
<P>
<I>Retinoic acid:</I>
</P>
<P>50 children randomised to myeloablative therapy received 13-cis-retinoic acid (whereas 48 did not) and 52 children randomised to conventional chemotherapy received 13-cis-retinoic acid (whereas 53 did not). Treatment with 13-cis-retinoic acid was part of a second randomisation (see notes); not all patients included in the first randomisation were eligible for inclusion in the second one.</P>
<P>
<I>Supportive care:</I>
</P>
<P>Prophylactic antibiotics not mentioned, growth factors: 250 mcg/m<SUP>2</SUP>/day intravenously in patients undergoing myeloablative therapy and 5 mcg/kg/day s.c. in patients undergoing maintenance therapy, granulocyte infusions not reported, other not reported.</P>
<P>
<I>Response before randomisation: </I>
</P>
<P>Complete remission n = 117, (very good) partial remission n = 147, stable disease or mixed response n = 34, progressive disease n = 52, not mentioned n = 29. Response was assessed by use of the International Neuroblastoma Remission Criteria (<LINK REF="REF-Brodeur-1988" TYPE="REFERENCE">Brodeur 1988</LINK>; <LINK REF="REF-Brodeur-1993" TYPE="REFERENCE">Brodeur 1993</LINK>)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-19 11:27:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Myeloablative therapy (n</I> = <I>189):</I>
</P>
<P>According to protocol: carboplatin 1000 mg/m<SUP>2</SUP>, 96-hour continuous infusion, day -8; etoposide 640 mg/m<SUP>2</SUP>, 96-hour continuous infusion, day -8; melphalan 140 mg/m<SUP>2</SUP> and 70 mg/m<SUP>2 </SUP>bolus infusion, days -7 and -6. Cumulative doses not mentioned. Total body irradiation: 333 cGy/day, days -3, -2, -1. Actually received cumulative doses not reported.</P>
<P>Source of stem cells: bone marrow</P>
<P>Timing of cell harvest: between 3rd and 4th and 4th and 5th cycles of induction regimen</P>
<P>Timing of stem cell rescue: after 5th induction chemotherapy cycle</P>
<P>Number of cells infused: 2 X 10<SUP>8</SUP> mnc/kg, day 0 (median dose)</P>
<P>Contamination with tumour cells: no</P>
<P>Purging: yes (performed by sedimentation, filtration, immunomagnetic separation)</P>
<P>
<I>Conventional therapy (n = 190):</I>
</P>
<P>According to protocol: 3 cycles of cisplatin 160 mg/m<SUP>2</SUP>; etoposide 500 mg/m<SUP>2</SUP>; doxorubicin 40 mg/m<SUP>2 </SUP>96 hours continuous infusion; simultaneously with bolus ifosfamide 2500 mg/m<SUP>2</SUP> + mesna 1500 mg/m<SUP>2 </SUP>days 0 to 3. Actually received cumulative doses were not reported </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:38:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Event-free survival</I> (defined as the time from randomisation to disease progression, death from any cause and a second neoplasm, whichever occurred first).</P>
<P>
<I>Overall survival</I> (definition not reported).</P>
<P>
<I>Adverse effects</I>, i.e. treatment-related death, secondary malignant disease, veno-occlusive disease, interstitial pneumonitis, renal effects, sepsis, serious infections (according to the common toxicity criteria of the National Cancer Institute).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-19 11:27:34 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow up not reported.</P>
<P>In this study a second randomisation was included to answer the question of whether subsequent treatment with 13-cis-retinoic acid (isotretinoin) could further improve event-free survival.</P>
<P>Additional follow-up data of this study have been published (<LINK REF="REF-Matthay-2009" TYPE="REFERENCE">Matthay 2009</LINK>): for response before randomisation slightly different numbers of patients were reported (i.e. complete remission n = 117, (very good) partial remission n = 148 (instead of 147), stable disease or mixed response n = 34, progressive disease n = 46 (instead of 52), not mentioned n = 34 (instead of 29). The length of follow-up was not reported, but the median follow-up of patients alive without an event was 7.7 years (range 130 days to 12.8 years). In this publication another definition of event-free survival was used (relapse was included as an event): the time from randomisation to disease progression, relapse, death from any cause and a second neoplasm, whichever occurred first)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-29 13:38:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pritchard-2005">
<CHAR_METHODS MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation was performed at the co-ordinating data centre by means of a minimisation technique using stages (III or IV) and individual participating centres as stratification factors.</P>
<P>Time of randomisation not reported (the decision to randomise was made 5 to 9 months after diagnosis).</P>
<P>Patients were randomised to myeloablative therapy or no further treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-19 11:27:53 +0200" MODIFIED_BY="[Empty name]">
<P>65 children with high-risk neuroblastoma.</P>
<P>
<I>High-risk neuroblastoma was defined as</I>: age &gt; 6 months, stage III or IV. Staging was done using the Evans staging criteria (<LINK REF="REF-Evans-1971" TYPE="REFERENCE">Evans 1971</LINK>).</P>
<P>
<I>Age</I>: 5 patients &lt; 1 year and 60 patients &gt; 1 year</P>
<P>
<I>Sex:</I> 34 males and 31 females</P>
<P>S<I>tage of disease</I>: I (n = 0), II (n = 0), III (n = 13), IVS (n = 0) and IV (n = 52)</P>
<P>
<I>Primary disease or recurrence</I>: not reported</P>
<P>
<I>Histology</I>: not reported</P>
<P>
<I>Bone metastases</I>: yes n = 40/52 stage IV patients, unclear n = 12/52 stage IV patients</P>
<P>
<I>Immunocytologic analysis of bone marrow at diagnosis</I>: not reported</P>
<P>
<I>MYCN amplification</I>: not reported</P>
<P>
<I>Serum LDH level: </I>not reported</P>
<P>
<I>Induction regimen</I>:</P>
<P>According to protocol all patients received vincristine 1.5 mg/m<SUP>2</SUP> on day 1, cyclophosphamide 600 mg/m<SUP>2</SUP> on day 1, cisplatin 60 mg/m<SUP>2 </SUP>on day 2, and teniposide 150 mg/m<SUP>2 </SUP>on day 4 repeated every 21 days or as soon as possible afterwards if recovery of neutrophil and platelet counts was slow. Cumulative doses not reported.</P>
<P>
<I>External radiotherapy</I>:</P>
<P>No</P>
<P>
<I>Surgery:</I>
</P>
<P>Surgery was performed before randomisation took place.</P>
<P>
<I>Therapeutic MIBG-I<SUP>131:</SUP>
</I>
</P>
<P>No</P>
<P>
<I>Immunotherapy:</I>
</P>
<P>No</P>
<P>
<I>Retinoic acid:</I>
</P>
<P>No</P>
<P>
<I>Supportive care:</I>
</P>
<P>Prophylactic antibiotics not mentioned, growth factors no, granulocyte infusions not mentioned, other: nutritional supplementation (n = not reported).</P>
<P>
<I>Response before randomisation: </I>
</P>
<P>Complete remission n = 36, good partial remission n = 29. This study was carried out and completed prior to the publication of the International Neuroblastoma Remission Criteria, but the definitions used in this study were agreed unanimously by the trialists as they were considered to be "standard practice" at the time of the study. Complete remission was defined as disappearance of primary tumour as judged by abdominal imaging and of secondary deposits and normal urine catecholamine metabolite levels. Good partial remission was defined as (a) shrinkage of primary tumour by more than 50% in each of three dimensions, (b) reduction of urine catecholamine metabolite levels by more than 50% of the original values and (c) disappearance of secondary deposits including bone marrow involvement. In both types of response, however, isotope bone scan appearances need not have normalised as long as there was improvement at all sites reported as abnormal on the scan performed at diagnosis, with no new lesions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-19 11:28:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Myeloablative therapy (n = 32):</I>
</P>
<P>According to protocol: melphalan 180 mg/ m<SUP>2</SUP>, i.v. bolus, 4 to 8 weeks after surgery or final course of chemotherapy (whichever came first). Cumulative doses not reported. Total body irradiation not reported.</P>
<P>Source of stem cells: bone marrow</P>
<P>Timing of cell harvest: the day before melphalan</P>
<P>Timing of stem cell rescue: after induction regimens</P>
<P>Contamination with tumour cells: not reported</P>
<P>Number of cells infused: 4.6 X 10<SUP>8</SUP> nucleated cells of bone marrow per kg (range 1.8 to 14.2)</P>
<P>Purging: no</P>
<P>
<I>Conventional therapy (n = 33):</I>
</P>
<P>No further treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 13:38:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<I>Event-free survival</I> (defined as the time to relapse or death prior to relapse from randomisation).</P>
<P>
<I>Overall survival</I> (defined as the time to death from any cause from randomisation).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:38:57 +0200" MODIFIED_BY="[Empty name]">
<P>Length of follow up not mentioned (median follow up for 21 surviving children was 14.3 years from randomisation (range 8.8 to 17.1 years)).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>i.v.: intravenous; LDH: lactate dehydrogenase; s.c.: subcutaneous; vs: versus; *: it should be noted that in the study describing additional follow-up this was not reported and the associated risk of detection bias was thus unclear for all outcomes </P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-04-12 08:59:48 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-04-09 12:50:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adkins-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 12:50:42 +0200" MODIFIED_BY="[Empty name]">
<P>Patients also included in <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berthold-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:26 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castel-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:27 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:28 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:19:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dini-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:19:15 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:19:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dini-1991a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:19:46 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:30:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dini-1991b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:30:58 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garaventa-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:29 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT; all patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 12:51:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haas_x002d_Kogan-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 12:51:52 +0200" MODIFIED_BY="[Empty name]">
<P>Patients also included in <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:20:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hartmann-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:20:44 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaneko-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:33 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:18:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klingebiel-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:18:15 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent transplant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ladenstein-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:34 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT; all patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ladenstein-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:35 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT; all patients with stage IV underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:23:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madon-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:23:18 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation between chemotherapy and chemotherapy + immunotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthay-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:36 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:23:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthay-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:23:45 +0200" MODIFIED_BY="[Empty name]">
<P>Review of different study protocols</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matthay-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:37 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mugishima-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:38 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT; review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohnuma-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:40 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olgun-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:41 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT (even though this was stated in the abstract)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paolucci-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:42 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:26:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Philip-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:26:17 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 12:51:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pinkerton-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 12:51:46 +0200" MODIFIED_BY="[Empty name]">
<P>Preliminary results of <LINK REF="STD-Pritchard-2005" TYPE="STUDY">Pritchard 2005</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saarinen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:43 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sawaguchi-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:44 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sawaguchi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:45 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 12:51:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 12:51:42 +0200" MODIFIED_BY="[Empty name]">
<P>Patients also included in <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:29:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seeger-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:29:52 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-09 12:52:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seeger-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-09 12:52:21 +0200" MODIFIED_BY="[Empty name]">
<P>Patients also included in <LINK REF="STD-Matthay-1999" TYPE="STUDY">Matthay 1999</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shuster-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:47 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stram-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:47 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-12 08:59:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stram-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-12 08:59:48 +0200" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 15:24:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zucker-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 15:24:17 +0200" MODIFIED_BY="[Empty name]">
<P>All patients underwent BMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial; BMT: bone marrow transplant</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-09-29 14:01:18 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-09-29 14:01:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hero-2010">
<CHAR_METHODS MODIFIED="2015-09-29 13:38:58 +0200" MODIFIED_BY="[Empty name]">
<P>No information on method of randomisation provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-29 13:38:59 +0200" MODIFIED_BY="[Empty name]">
<P>295 children with high-risk neuroblastoma (defined as stage 4 or MYCN amplified).</P>
<P>No information was provided on age, sex, stage of disease, primary disease or recurrence, histology, presence of bone metastases, immunocytologic analysis of bone marrow at diagnosis, MYCN amplification, serum LDH level, treatment details, response before randomisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-29 13:39:00 +0200" MODIFIED_BY="[Empty name]">
<P>Myeloablative therapy (n=143) versus conventional therapy, i.e. 4 cycles of oral cyclophosphamide (n=119). For 33 patients no information was provided.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-29 14:01:18 +0200" MODIFIED_BY="[Empty name]">
<P>Relapses occurred statistically significantly (P &lt; 0.001) later in the transplant group (74 out of 143 (52%) patients; median 21 months (range 8 to 85 months)) than in the control group (83 out of 119 (70%) patients; median 16 months (range 7 to 60 months, median 16 months)).  </P>
<P>Patients died up to nine years after diagnosis: in the transplant group at a median of 30 months; in the control group at a median of 20 months (P &lt; 0.001).</P>
<P>Early complications (the abstract did not report if these were significant statistical differences): (a) pneumonia n = 10 in the transplant group versus n = 1 in the control group, (b) other severe infectious complications n = 8 in the transplant group, (c) veno-occlusive disease n = 8 in the transplant group, (d) renal failure n = 3 in the transplant group, (e) treatment-related death n = 5 in the transplant group versus n = 0 in the control group.</P>
<P>Secondary malignant disease: 1 in each treatment group (both leukaemia cases; no further information provided).</P>
<P>Major late effects in 109 patients surviving 5 years or longer, i.e. n = 68 in the transplant group versus n = 41 in the control group (it was unclear if this were all patients who survived 5 years or longer): (a) hearing loss 72% versus 51% (P = 0.04), (b) tubular damage 18% versus 12% (NS), (c) hypothyroidism 19% versus 2% (P = 0.02), (d) focal nodular hyperplasia of the liver 10% versus 0 % (P = 0.04), (e) impaired growth 10% versus 0% (P = 0.04).</P>
<P>In conclusion: myeloablative therapy proved effective with respect to long-term outcome, but is complicated by acute and long-term toxicity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-29 13:39:13 +0200" MODIFIED_BY="[Empty name]">
<P>This study has not been published in full text (April 2015), but was presented at the ANR conference 2010.</P>
<P>It provides additional follow-up of the <LINK REF="STD-Berthold--2005" TYPE="STUDY">Berthold 2005</LINK> study.</P>
<P>Length of follow-up was up to 12 years (median observation time 8.4 years).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>LDH: lactate dehydrogenase; NS: not significant</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-06-04 14:21:27 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-09-29 13:38:53 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:10 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>Randomisation was performed centrally by computer-generated sequence with a block size of 8.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Randomisation was performed by permuted-block design; no further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>Randomisation was performed at the co-ordinating data centre by means of a minimisation technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:10 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>Randomisation was performed centrally by computer-generated sequence with a block size of 8.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Randomisation was performed by permuted-block design; no further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>Randomisation was performed at the co-ordinating data centre by means of a minimisation technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-05-25 15:04:53 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-07-14 14:21:10 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-14 14:20:53 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>Participants and personnel were not blinded. However, it should be noted that due to the nature of the interventions blinding of participants and personnel was virtually impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-14 14:21:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Participants and personnel were not blinded. However, it should be noted that due to the nature of the interventions blinding of participants and personnel was virtually impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-14 14:21:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>No information on blinding of participants and personnel was provided. However, it should be noted that due to the nature of the interventions blinding of participants and personnel was virtually impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-09-29 13:38:53 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.04" NO="4">
<NAME>Adverse effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.03" NO="3">
<NAME>Overall survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Event-free survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-14 14:20:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-07-14 14:20:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-07-14 14:20:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-14 14:21:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Outcome assessors were blinded*.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-09-29 13:38:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Outcome assessors were blinded. In the additional follow-up study no information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-07-14 14:21:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Outcome assessors were blinded*.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-14 14:21:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2015-07-14 14:21:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>No information on blinding of outcome assessors was provided, but since this is not applicable for overall survival we judged this as a low risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-06-25 15:10:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-06-25 13:26:27 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Event-free survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Overall survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>Adverse effects</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:12 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Incomplete outcome data (attrition bias) Event-free survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:13 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Incomplete outcome data (attrition bias) Overall survival</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:06 +0200" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Incomplete outcome data (attrition bias) Adverse effects except treatment-related death</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>It was not clear if all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-25 15:10:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:07 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Incomplete outcome data (attrition bias) Treatment-related death</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>All participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>Not all participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-25 15:10:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-07-14 14:21:14 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:20:59 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but not all expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but all expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>There was no protocol mentioned in the manuscript (and we did not search for it), but not all expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-09-29 13:38:45 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-29 13:38:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berthold--2005">
<DESCRIPTION>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported).</P>
<P>
<I>Inappropriate influence of funders: </I>not present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matthay-1999">
<DESCRIPTION>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (no information provided).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-14 14:21:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pritchard-2005">
<DESCRIPTION>
<P>
<I>Difference in length of follow-up between treatment arms:</I> unclear (not reported)</P>
<P>
<I>Inappropriate influence of funders: </I>unclear (no information provided).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-06-04 14:21:27 +0200" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2015-06-25 14:10:55 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-06-24 14:26:26 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-06-24 14:26:26 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Myeloablative therapy versus control</NAME>
<IV_OUTCOME CHI2="0.8599277108433734" CI_END="0.8974450621346564" CI_START="0.6723006521705963" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.776757942064586" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.046992127643272645" LOG_CI_START="-0.1724364674542547" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10971429754876366" MODIFIED="2013-08-19 13:50:16 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6505326273111012" P_Q="0.7170847563195011" P_Z="6.071721169703818E-4" Q="0.13130317552738835" RANDOM="YES" SCALE="2.28" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="369" WEIGHT="100.0" Z="3.4283901865752022">
<NAME>Event-free survival without additional follow-up data</NAME>
<GROUP_LABEL_1>Myeloablative therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transplant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.7286245353159853" CI_END="0.9169584097231809" CI_START="0.672067795855365" DF="1" EFFECT_SIZE="0.7850211572395351" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.03765036208062659" LOG_CI_START="-0.17258691462361678" LOG_EFFECT_SIZE="-0.10511863835212165" MODIFIED="2013-07-04 15:21:13 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3933294203310119" P_Z="0.002260282813419995" STUDIES="2" TAU2="0.0" TOTAL_1="338" TOTAL_2="336" WEIGHT="86.42570281124497" Z="3.053712895301805">
<NAME>Event-free survival including secondary malignant disease as an event without additional follow-up data</NAME>
<IV_DATA CI_END="0.9275536133596521" CI_START="0.5572199030303318" EFFECT_SIZE="0.7189237334319262" ESTIMABLE="YES" ESTIMATE="-0.33" LOG_CI_END="-0.03266097841014185" LOG_CI_START="-0.2539733796460044" LOG_EFFECT_SIZE="-0.14331717902807312" MODIFIED="2009-08-26 13:15:00 +0200" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.13" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" WEIGHT="32.1285140562249"/>
<IV_DATA CI_END="1.0060144128403612" CI_START="0.6797729739095437" EFFECT_SIZE="0.8269591339433623" ESTIMABLE="YES" ESTIMATE="-0.19" LOG_CI_END="0.0026042027598677294" LOG_CI_START="-0.16763610588310346" LOG_EFFECT_SIZE="-0.08251595156161787" MODIFIED="2009-08-26 14:07:05 +0200" MODIFIED_BY="[Empty name]" ORDER="10" SE="0.1" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" WEIGHT="54.29718875502008"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.0746476032503927" CI_START="0.4906654259947105" DF="0" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.03126607443393062" LOG_CI_START="-0.3092145428520118" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2013-07-04 15:21:30 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10959858339495472" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="13.57429718875502" Z="1.5999999999999999">
<NAME>Event-free survival not including secondary malignant disease as an event without additional follow-up data</NAME>
<IV_DATA CI_END="1.0746476032503927" CI_START="0.4906654259947105" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.03126607443393062" LOG_CI_START="-0.3092145428520118" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2009-08-26 13:48:27 +0200" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.2" STUDY_ID="STD-Pritchard-2005" TOTAL_1="32" TOTAL_2="33" WEIGHT="13.57429718875502"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.18431779726196" CI_END="0.9002605999015655" CI_START="0.6991574489822742" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.7933624042305195" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.045631756430815115" LOG_CI_START="-0.1554250109150244" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10052838367291977" MODIFIED="2013-08-19 13:48:17 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.553132061108123" P_Q="0.6400685388779922" P_Z="3.3176297702605217E-4" Q="0.21865256121045765" RANDOM="YES" SCALE="2.35" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="369" WEIGHT="100.0" Z="3.5891460244724733">
<NAME>Event-free survival including additional follow-up data of Matthay 1999</NAME>
<GROUP_LABEL_1>Myeloablative therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transplant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.9656652360515023" CI_END="0.9160684898650053" CI_START="0.7013562720946767" DF="1" EFFECT_SIZE="0.8015549769261745" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.038072055089271396" LOG_CI_START="-0.15406131484457924" LOG_EFFECT_SIZE="-0.09606668496692534" MODIFIED="2013-07-04 15:25:33 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32576383911451134" P_Z="0.0011677912851178315" STUDIES="2" TAU2="0.0" TOTAL_1="338" TOTAL_2="336" WEIGHT="89.60159975388402" Z="3.2466323700408424">
<NAME>Event-free survival including additional follow-up data and secondary malignant disease as an event</NAME>
<IV_DATA CI_END="0.9275536133596521" CI_START="0.5572199030303318" EFFECT_SIZE="0.7189237334319262" ESTIMABLE="YES" ESTIMATE="-0.33" LOG_CI_END="-0.03266097841014185" LOG_CI_START="-0.2539733796460044" LOG_EFFECT_SIZE="-0.14331717902807312" MODIFIED="2012-11-11 20:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.13" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" WEIGHT="24.61159821565913"/>
<IV_DATA CI_END="0.9770642356629861" CI_START="0.7140536933046407" EFFECT_SIZE="0.835270211411272" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="-0.010076883285396855" LOG_CI_START="-0.14626913019977378" LOG_EFFECT_SIZE="-0.07817300674258534" MODIFIED="2012-11-12 13:40:11 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SE="0.08" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" WEIGHT="64.99000153822489"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.0746476032503927" CI_START="0.4906654259947105" DF="0" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.03126607443393062" LOG_CI_START="-0.3092145428520118" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2013-07-04 15:25:42 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10959858339495472" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="10.398400246115981" Z="1.5999999999999999">
<NAME>Event-free survival including additional follow-up data and not including secondary malignant disease as an event</NAME>
<IV_DATA CI_END="1.0746476032503927" CI_START="0.4906654259947105" EFFECT_SIZE="0.7261490370736909" ESTIMABLE="YES" ESTIMATE="-0.32" LOG_CI_END="0.03126607443393062" LOG_CI_START="-0.3092145428520118" LOG_EFFECT_SIZE="-0.13897423420904056" MODIFIED="2012-11-12 13:40:10 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.2" STUDY_ID="STD-Pritchard-2005" TOTAL_1="32" TOTAL_2="33" WEIGHT="10.398400246115981"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.13238512035010935" CI_END="0.980929846610952" CI_START="0.5653512672083286" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.7446945224882301" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.008362051049399506" LOG_CI_START="-0.24768163004292684" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1280218405461632" MODIFIED="2013-08-19 13:48:33 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7159718594858913" P_Q="1.0" P_Z="0.0359997765954116" Q="0.0" RANDOM="YES" SCALE="6.62" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="179" WEIGHT="100.0" Z="2.0969299524949925">
<NAME>Overall survival without additional follow-up data</NAME>
<GROUP_LABEL_1>Myeloablative therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transplant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0759391169427959" CI_START="0.5525596556610768" EFFECT_SIZE="0.7710515858035663" ESTIMABLE="YES" ESTIMATE="-0.26" LOG_CI_END="0.03178769705168002" LOG_CI_START="-0.257620827641371" LOG_EFFECT_SIZE="-0.11291656529484549" MODIFIED="2009-09-04 13:56:44 +0200" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.17" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" WEIGHT="68.38074398249452"/>
<IV_DATA CI_END="1.127486699795654" CI_START="0.4231658924291582" EFFECT_SIZE="0.6907343306373547" ESTIMABLE="YES" ESTIMATE="-0.37" LOG_CI_END="0.05211142749951079" LOG_CI_START="-0.3734893441079172" LOG_EFFECT_SIZE="-0.16068895830420316" MODIFIED="2009-09-04 13:56:49 +0200" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.25" STUDY_ID="STD-Pritchard-2005" TOTAL_1="32" TOTAL_2="33" WEIGHT="31.619256017505474"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="1.6823784578623284" CI_END="1.0075725512117588" CI_START="0.7320720464360756" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.8588455620764479" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.0032763277228166536" LOG_CI_START="-0.13544617600456504" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.06608492414087423" MODIFIED="2013-08-19 13:48:49 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.43119769933791785" P_Q="1.0" P_Z="0.06184802421033765" Q="0.0" RANDOM="YES" SCALE="2.31" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="370" TOTAL_2="369" WEIGHT="100.0" Z="1.8673837013743138">
<NAME>Overall survival including additional follow-up data of Matthay 1999</NAME>
<GROUP_LABEL_1>Myeloablative therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transplant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0759391169427959" CI_START="0.5525596556610768" EFFECT_SIZE="0.7710515858035663" ESTIMABLE="YES" ESTIMATE="-0.26" LOG_CI_END="0.03178769705168002" LOG_CI_START="-0.257620827641371" LOG_EFFECT_SIZE="-0.11291656529484549" MODIFIED="2012-11-11 20:57:57 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.17" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" WEIGHT="22.975829427442328"/>
<IV_DATA CI_END="1.1229918276192528" CI_START="0.7588156636658342" EFFECT_SIZE="0.9231163463866358" ESTIMABLE="YES" ESTIMATE="-0.08" LOG_CI_END="0.050376595769225437" LOG_CI_START="-0.11986371287374573" LOG_EFFECT_SIZE="-0.03474355855226016" MODIFIED="2012-11-12 13:40:59 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.1" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" WEIGHT="66.40014704530833"/>
<IV_DATA CI_END="1.127486699795654" CI_START="0.4231658924291582" EFFECT_SIZE="0.6907343306373547" ESTIMABLE="YES" ESTIMATE="-0.37" LOG_CI_END="0.05211142749951079" LOG_CI_START="-0.3734893441079172" LOG_EFFECT_SIZE="-0.16068895830420316" MODIFIED="2012-11-12 13:40:58 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.25" STUDY_ID="STD-Pritchard-2005" TOTAL_1="32" TOTAL_2="33" WEIGHT="10.624023527249335"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="23.686075106533412" CI_END="1.2761526064015902" CI_START="0.9311136956862337" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0900656721529232" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="176" I2="70.44677107323211" I2_Q="70.31504537044965" ID="CMP-001.05" LOG_CI_END="0.10590261181084956" LOG_CI_START="-0.030997285297544377" LOG_EFFECT_SIZE="0.03745266325665257" METHOD="MH" MODIFIED="2015-06-24 14:26:26 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.001293477018210254" P_Q="0.0048062814929652475" P_Z="0.28353946470769775" Q="16.84354940877246" RANDOM="YES" SCALE="118.63" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2135569036673962" TOTALS="SUB" TOTAL_1="1372" TOTAL_2="1392" WEIGHT="600.0" Z="1.0724021370158487">
<NAME>Adverse effects grade 3 or higher without additional follow-up data</NAME>
<GROUP_LABEL_1>Myeloablative therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transplant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.532300312361288" CI_END="37.11589400255468" CI_START="0.17216243234784262" DF="1" EFFECT_SIZE="2.527837532406804" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="77.93614873064294" ID="CMP-001.05.01" LOG_CI_END="1.5695599257724513" LOG_CI_START="-0.7640616101645885" LOG_EFFECT_SIZE="0.40274915780393145" MODIFIED="2009-09-08 13:18:26 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03326093217519388" P_Z="0.49870891224524494" STUDIES="2" TAU2="2.9432276237075836" TOTAL_1="278" TOTAL_2="296" WEIGHT="99.99999999999999" Z="0.6765225911257973">
<NAME>Treatment-related death</NAME>
<DICH_DATA CI_END="3.2265821347088117" CI_START="0.16738362794109923" EFFECT_SIZE="0.7348993288590604" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.508742724827243" LOG_CI_START="-0.7762870232995168" LOG_EFFECT_SIZE="-0.1337721492361369" MODIFIED="2009-09-08 13:03:09 +0200" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.7548328350495008" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" VAR="0.5697726088688669" WEIGHT="53.48818650458834"/>
<DICH_DATA CI_END="81.49830858047305" CI_START="1.343815112755502" EFFECT_SIZE="10.465116279069768" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.9111485954664824" LOG_CI_START="0.12833952092503204" LOG_EFFECT_SIZE="1.019744058195757" MODIFIED="2009-09-08 13:18:26 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.0472308754328954" STUDY_ID="STD-Matthay-1999" TOTAL_1="129" TOTAL_2="150" VAR="1.0966925064599484" WEIGHT="46.511813495411644"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.650494966021058E-4" CI_END="7.004168391037709" CI_START="0.1406349919395578" DF="1" EFFECT_SIZE="0.992487362749216" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.8453565786477559" LOG_CI_START="-0.8519066073708464" LOG_EFFECT_SIZE="-0.003275014361545263" MODIFIED="2009-09-08 13:18:38 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9897497321007638" P_Z="0.993964989576695" STUDIES="2" TAU2="0.0" TOTAL_1="338" TOTAL_2="336" WEIGHT="100.0" Z="0.0075638360041702605">
<NAME>Secondary malignant disease</NAME>
<DICH_DATA CI_END="15.518844375417343" CI_START="0.06186909975653798" EFFECT_SIZE="0.9798657718120806" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1908593780004262" LOG_CI_START="-1.2085262032561002" LOG_EFFECT_SIZE="-0.008833412627836929" MODIFIED="2009-09-08 13:14:14 +0200" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="1.409410967580263" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" VAR="1.9864392755355336" WEIGHT="50.03780996172884"/>
<DICH_DATA CI_END="15.954828396063869" CI_START="0.06334195393592092" EFFECT_SIZE="1.0052910052910053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2028921374519157" LOG_CI_START="-1.1983085438927459" LOG_EFFECT_SIZE="0.002291796779584843" MODIFIED="2009-09-08 13:18:38 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="1.410477166356924" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="1.9894458368142578" WEIGHT="49.96219003827116"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2297753252238648" CI_START="0.8384698089655649" DF="0" EFFECT_SIZE="1.0154454598899043" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="99" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.08982577491238335" LOG_CI_START="-0.07651257054831352" LOG_EFFECT_SIZE="0.006656602182034894" MODIFIED="2009-10-20 10:26:18 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8753477546504382" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="0.15686942779266566">
<NAME>Serious infections</NAME>
<DICH_DATA CI_END="1.2297753252238648" CI_START="0.8384698089655649" EFFECT_SIZE="1.0154454598899043" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="99" LOG_CI_END="0.08982577491238335" LOG_CI_START="-0.07651257054831352" LOG_EFFECT_SIZE="0.006656602182034894" MODIFIED="2009-10-20 10:26:18 +0200" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.0977079675117028" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.00954684691526797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2955964903671502" CI_START="0.6667365316616543" DF="0" EFFECT_SIZE="0.9294199860237596" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="53" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.11246976288225428" LOG_CI_START="-0.17604574846763538" LOG_EFFECT_SIZE="-0.03178799279269055" MODIFIED="2009-10-20 10:38:37 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6658221759426624" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="0.43188888336014325">
<NAME>Sepsis</NAME>
<DICH_DATA CI_END="1.2955964903671502" CI_START="0.6667365316616543" EFFECT_SIZE="0.9294199860237596" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="53" LOG_CI_END="0.11246976288225428" LOG_CI_START="-0.17604574846763538" LOG_EFFECT_SIZE="-0.03178799279269055" MODIFIED="2009-10-20 10:38:37 +0200" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.16947543954173971" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.028721924607865875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.042121529905589" CI_START="1.2845456498308492" DF="0" EFFECT_SIZE="2.2786596119929454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="0.6066093668175684" LOG_CI_START="0.10874954271474908" LOG_EFFECT_SIZE="0.3576794547661587" MODIFIED="2009-10-20 10:32:05 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.004859392715419426" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="2.81620976593128">
<NAME>Renal effects</NAME>
<DICH_DATA CI_END="4.042121529905589" CI_START="1.2845456498308492" EFFECT_SIZE="2.2786596119929454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" LOG_CI_END="0.6066093668175684" LOG_CI_START="0.10874954271474908" LOG_EFFECT_SIZE="0.3576794547661587" MODIFIED="2009-10-20 10:32:05 +0200" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.29244532512387145" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.08552426818680688" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.43153755613746" CI_START="2.255851706193513" DF="0" EFFECT_SIZE="9.55026455026455" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" ID="CMP-001.05.06" LOG_CI_END="1.6067202572735482" LOG_CI_START="0.3533105468633171" LOG_EFFECT_SIZE="0.9800154020684326" MODIFIED="2009-11-30 14:44:20 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.0021773444545935246" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="3.064911459350363">
<NAME>Interstitial pneumonitis</NAME>
<DICH_DATA CI_END="40.43153755613746" CI_START="2.255851706193513" EFFECT_SIZE="9.55026455026455" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" LOG_CI_END="1.6067202572735482" LOG_CI_START="0.3533105468633171" LOG_EFFECT_SIZE="0.9800154020684326" MODIFIED="2009-10-20 10:38:41 +0200" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.7362590683731007" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.5420774157616262" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.28028143432012" CI_END="1.265808848746307" CI_START="0.9365327290949338" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0887935596929728" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="197" I2="61.70737291353773" I2_Q="69.82383922151857" ID="CMP-001.06" LOG_CI_END="0.10236812732230136" LOG_CI_START="-0.028477040694558645" LOG_EFFECT_SIZE="0.03694554331387132" METHOD="MH" MODIFIED="2015-06-24 14:26:22 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.010767457204732933" P_Q="0.005393238083952756" P_Z="0.2683657630140476" Q="16.569370890830786" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11821838445633055" TOTALS="SUB" TOTAL_1="1365" TOTAL_2="1380" WEIGHT="600.0" Z="1.106833907311302">
<NAME>Adverse effects grade 3 or higher including additional follow-up of Matthay 1999</NAME>
<GROUP_LABEL_1>Myeloablative therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours transplant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2893469102010898" CI_END="1.7838103685606872" CI_START="0.6484541421937259" DF="1" EFFECT_SIZE="1.0755088202247785" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.2513486839722593" LOG_CI_START="-0.18812073121661582" LOG_EFFECT_SIZE="0.03161397637782181" MODIFIED="2013-07-02 11:11:25 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5906394238917876" P_Z="0.7779537436170486" STUDIES="2" TAU2="0.0" TOTAL_1="271" TOTAL_2="284" WEIGHT="100.00000000000001" Z="0.28198665466628925">
<NAME>Treatment-related death</NAME>
<DICH_DATA CI_END="3.2265821347088117" CI_START="0.16738362794109923" EFFECT_SIZE="0.7348993288590604" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.508742724827243" LOG_CI_START="-0.7762870232995168" LOG_EFFECT_SIZE="-0.1337721492361369" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.7548328350495008" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" VAR="0.5697726088688669" WEIGHT="11.695827340842353"/>
<DICH_DATA CI_END="1.9379986260853195" CI_START="0.6602144822247829" EFFECT_SIZE="1.1311475409836065" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.28735346482838126" LOG_CI_START="-0.18031495337540476" LOG_EFFECT_SIZE="0.05351925572648825" MODIFIED="2012-11-12 13:41:11 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.27471074384890976" STUDY_ID="STD-Matthay-1999" TOTAL_1="122" TOTAL_2="138" VAR="0.0754659927860213" WEIGHT="88.30417265915766"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1487395468704797" CI_END="9.01334878949421" CI_START="0.2422340421138016" DF="1" EFFECT_SIZE="1.4776129094795847" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.9548861772821428" LOG_CI_START="-0.6157648237723254" LOG_EFFECT_SIZE="0.16956067675490868" MODIFIED="2012-11-12 13:27:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6997429640797752" P_Z="0.6721650774357895" STUDIES="2" TAU2="0.0" TOTAL_1="338" TOTAL_2="336" WEIGHT="100.0" Z="0.423178439272308">
<NAME>Secondary malignant disease</NAME>
<DICH_DATA CI_END="15.518844375417343" CI_START="0.06186909975653798" EFFECT_SIZE="0.9798657718120806" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1908593780004262" LOG_CI_START="-1.2085262032561002" LOG_EFFECT_SIZE="-0.008833412627836929" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="1.409410967580263" STUDY_ID="STD-Berthold--2005" TOTAL_1="149" TOTAL_2="146" VAR="1.9864392755355336" WEIGHT="42.850836223621684"/>
<DICH_DATA CI_END="21.986315437812713" CI_START="0.18386164033304514" EFFECT_SIZE="2.0105820105820107" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.342152454503962" LOG_CI_START="-0.7355088696168302" LOG_EFFECT_SIZE="0.30332179244356605" MODIFIED="2012-11-12 13:27:33 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="1.2204285463779754" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="1.4894458368142578" WEIGHT="57.14916377637831"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2297753252238648" CI_START="0.8384698089655649" DF="0" EFFECT_SIZE="1.0154454598899043" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="99" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.08982577491238335" LOG_CI_START="-0.07651257054831352" LOG_EFFECT_SIZE="0.006656602182034894" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8753477546504382" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="0.15686942779266566">
<NAME>Serious infections</NAME>
<DICH_DATA CI_END="1.2297753252238648" CI_START="0.8384698089655649" EFFECT_SIZE="1.0154454598899043" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="99" LOG_CI_END="0.08982577491238335" LOG_CI_START="-0.07651257054831352" LOG_EFFECT_SIZE="0.006656602182034894" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.0977079675117028" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.00954684691526797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2955964903671502" CI_START="0.6667365316616543" DF="0" EFFECT_SIZE="0.9294199860237596" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="53" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.11246976288225428" LOG_CI_START="-0.17604574846763538" LOG_EFFECT_SIZE="-0.03178799279269055" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6658221759426624" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="0.43188888336014325">
<NAME>Sepsis</NAME>
<DICH_DATA CI_END="1.2955964903671502" CI_START="0.6667365316616543" EFFECT_SIZE="0.9294199860237596" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="53" LOG_CI_END="0.11246976288225428" LOG_CI_START="-0.17604574846763538" LOG_EFFECT_SIZE="-0.03178799279269055" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.16947543954173971" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.028721924607865875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.042121529905589" CI_START="1.2845456498308492" DF="0" EFFECT_SIZE="2.2786596119929454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="0.6066093668175684" LOG_CI_START="0.10874954271474908" LOG_EFFECT_SIZE="0.3576794547661587" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.004859392715419426" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="2.81620976593128">
<NAME>Renal effects</NAME>
<DICH_DATA CI_END="4.042121529905589" CI_START="1.2845456498308492" EFFECT_SIZE="2.2786596119929454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="15" LOG_CI_END="0.6066093668175684" LOG_CI_START="0.10874954271474908" LOG_EFFECT_SIZE="0.3576794547661587" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.29244532512387145" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.08552426818680688" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="40.43153755613746" CI_START="2.255851706193513" DF="0" EFFECT_SIZE="9.55026455026455" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" ID="CMP-001.06.06" LOG_CI_END="1.6067202572735482" LOG_CI_START="0.3533105468633171" LOG_EFFECT_SIZE="0.9800154020684326" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.0021773444545935246" STUDIES="1" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="3.064911459350363">
<NAME>Interstitial pneumonitis</NAME>
<DICH_DATA CI_END="40.43153755613746" CI_START="2.255851706193513" EFFECT_SIZE="9.55026455026455" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" LOG_CI_END="1.6067202572735482" LOG_CI_START="0.3533105468633171" LOG_EFFECT_SIZE="0.9800154020684326" MODIFIED="2012-11-12 10:23:05 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.7362590683731007" STUDY_ID="STD-Matthay-1999" TOTAL_1="189" TOTAL_2="190" VAR="0.5420774157616262" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (it should be noted that in the study describing additional follow-up the associated risk of detection bias was thus unclear for all outcomes except overall survival)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdEAAAJLCAIAAAA3tDt0AAAigklEQVR42u3dsY4dRRaH8ZGQEIED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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.1 Event-free survival without additional follow-up data.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3AAAAEwCAMAAADB82OgAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.2 Event-free survival including additional follow-up data of Matthay 1999.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5EAAAEwCAMAAAAZ0wXvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.3 Overall survival without additional follow-up data.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0sAAACQCAMAAADuiwA1AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.4 Overall survival including additional follow-up data of Matthay 1999.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0sAAACgCAMAAADq8QeYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.5 Adverse effects grade 3 or higher without additional follow-up data.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvcAAAMQCAMAAACUl7oHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2015-09-29 13:38:54 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.06" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Myeloablative therapy versus control, outcome: 1.6 Adverse effects grade 3 or higher including additional follow-up of Matthay 1999.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvcAAAMQCAMAAACUl7oHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-05-25 15:04:53 +0200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2015-10-01 11:30:38 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-07-14 14:23:14 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-11-06 14:55:07 +0100" MODIFIED_BY="[Empty name]">Search strategy for Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-14 14:23:14 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>neuroblastoma</B> we have used the following subject headings and text words (both in the original version of the review and the updates):</P>
<P>(neuroblastoma OR neuroblastomas OR ganglioneuroblastoma OR ganglioneuroblastomas OR neuroepithelioma OR olfactory esthesioneuroblastoma OR neuroblast*) in Clinical Trials</P>
<P>(2) For <B>bone marrow and stem cell rescue</B> the following subject headings and text words were used (both in the original version of the review and the updates):</P>
<P>(stem cell rescue OR bone marrow rescue OR bone marrow transplantation OR bone marrow grafting OR bone marrow cell transplantation OR stem cell transplantation OR stem cell transplantations OR hematopoietic stem cell transplantation OR peripheral blood stem cell transplantation OR peripheral stem cell transplantation OR cord blood stem cell transplantation OR placental blood stem cell transplantation OR umbilical cord stem cell transplantation OR autograft OR autografts OR autologous transplantation OR autotransplant OR autotransplants OR ABMT OR transplant* OR autolog* OR BMT OR myeloablative therapy OR myeloablative agonist OR myeloablative agonists OR myeloablativ* OR mega therapy OR high-dose therapy OR high dose therapy) in Clinical Trials</P>
<P>(3) For <B>children</B> the following subject headings and text words were used (both in the original version of the review and the updates):</P>
<P>(infant OR infan* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy) in Clinical Trials</P>
<P>Finally, searches were combined as (1) AND (2) AND (3).</P>
<P>The search was performed in title, abstract or keywords.</P>
<P>[* = zero or more characters]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-10-01 11:30:38 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-11-06 15:29:43 +0100" MODIFIED_BY="[Empty name]">Search strategy for MEDLINE/PubMed</TITLE>
<APPENDIX_BODY MODIFIED="2015-10-01 11:30:38 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>neuroblastoma</B> we have used the following subject headings and text words (both in the original version of the review and the updates):</P>
<P>neuroblastoma OR neuroblastomas OR ganglioneuroblastoma OR ganglioneuroblastomas OR neuroepithelioma OR esthesioneuroblastoma, olfactory OR neuroblast*</P>
<P>(2) For <B>bone marrow and stem cell rescue</B> the following subject headings and text words were used (both in the original version of the review and the updates) :</P>
<P>stem cell rescue OR bone marrow rescue OR bone marrow transplantation OR bone marrow grafting OR bone marrow cell transplantation OR stem cell transplantation OR stem cell transplantations OR hematopoietic stem cell transplantation OR peripheral blood stem cell transplantation OR peripheral stem cell transplantation OR cord blood stem cell transplantation OR placental blood stem cell transplantation OR umbilical cord stem cell transplantation OR autograft OR autografts OR transplantation, autologous OR autotransplant OR autotransplants OR ABMT OR transplant* OR autolog* OR BMT OR myeloablative therapy OR myeloablative agonist OR myeloablative agonists OR myeloablativ* OR mega therapy OR high-dose therapy OR high dose therapy</P>
<P>(3) For <B>children</B> the following subject headings and text words were used (both in the original version of the review and the updates):</P>
<P>infant OR infan* OR child OR child* OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR teen* OR boy* OR girl* OR minors OR minors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy OR schools, nursery</P>
<P>(4) For identifying <B>RCTs and CCTs</B> we used the highly sensitive search strategy as described in the <I>Cochrane Handbook for Systematic Reviews of Interventons </I>(<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK> for the original version, and <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK> and <LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK> for the updates).</P>
<P>Finally, searches were combined as (1) AND (2) AND (3) AND (4).</P>
<P>[pt = publication type; tiab = title, abstract; sh = subject heading; mh = MeSH term; *=zero or more characters; RCT = randomized controlled trial; CCT = controlled clinical trial]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-07-14 14:23:19 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-11-06 15:29:36 +0100" MODIFIED_BY="[Empty name]">Search strategy for EMBASE/Ovid</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-14 14:23:19 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>neuroblastoma</B> we have used the following subject headings and text words (both in the original version of the review and the updates):</P>
<P>(neuroblastoma or neuroblastomas or ganglioneuroblastoma or ganglioneuroblastomas or neuroepithelioma or olfactory esthesioneuroblastoma or neuroblast$ or neuroganglioblastoma).mp or neuroblastoma/ or olfactory neuroepithelioma/ or neuroepithelioma/ or esthesioneuroblastoma/ or neuroblastoma cell/</P>
<P>(2) For <B>bone marrow and stem cell rescue</B> the following subject headings and text words were used (both in the original version of the review and the updates):</P>
<P>(stem cell rescue or bone marrow rescue).mp or (bone marrow transplantation or bone marrow grafting).mp or (bone marrow cell transplantation or stem cell transplantation or stem cell transplantations).mp or (hematopoietic stem cell transplantation or peripheral blood stem cell transplantation).mp or (peripheral stem cell transplantation or cord blood stem cell transplantation).mp or (placental blood stem cell transplantation or umbilical cord stem cell transplantation).mp or (autograft or autografts).mp or (autologous transplantation or autotransplant or autotransplants).mp or (BMT or ABMT or PBSCT).mp or transplant$.mp or autolog$.mp or (bone marrow transplant or bone marrow transfusion or bone marrow graft).mp or myeloablative therapy.mp or (myeloablative agonist or myeloablative agonists).mp or myeloablativ$.mp or mega therapy.mp or (high-dose therapy or high dose therapy).mp or autologous bone marrow transplantation/ or allogenic bone marrow transplantation/ or bone marrow transplantation/ or bone marrow rescue/ or myeloablative agent/ or stem cell transplantation/ or allogenic bone marrow transplantation/ or allogeneic stem cell transplantation/ or autologous stem cell transplantation/ or peripheral blood stem cell transplantation/ or cord blood stem cell transplantation/ or hematopoietic stem cell transplantation/ or autograft/ or autotransplantation/ or allotransplantation/</P>
<P>(3) For <B>children</B> the following subject headings and text words were used (both in the original version of the review and the updates):</P>
<P>Infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/ or adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/ or primary school/ or high school/ or kindergarten/ or nursery school/ or school/ or infant$.mp or newborn$.mp or new born$.mp or (baby or baby$ or babies).mp or neonate$.mp or child$.mp or (school child$ or schoolchild$).mp or (school age$ or schoolage$).mp or (pre school$ or preschool$).mp or (kid or kids).mp or toddler$.mp or adoles$.mp or teen$.mp or boy$.mp or girl$.mp or minors$.mp or (under ag$ or underage$).mp or juvenil$.mp or youth$.mp or puber$.mp or pubescen$.mp or prepubescen$.mp or prepubert$.mp or (pediatric$ or paediatric$ or peadiatric$).mp or (school or schools).mp or (high school$ or highschool$).mp or primary school$.mp or nursery school$.mp or elementary school.mp or secondary school$.mp or kindergar$.mp</P>
<P>(4) For <B>RCTs and CCTs</B> the following subject headings and text words were used (in the original version of the review):</P>
<P>(a) clinical trial/ or controlled study/ or randomized controlled trial/ or double blind procedure/ or single blind procedure/ or comparative study/ or randomization/ or prospective study/ or placebo/ or phase 2 clinical trial/ or phase 3 clinical study.mp or phase 4 clinical study.mp or phase 3 clinical trial/ or phase 4 clinical trial/ or allocat$.mp or blind$.mp or control$.mp or placebo$.mp or prospectiv$.mp or random$.mp or ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp or (versus or vs).mp or (randomized controlled trial$ or randomised controlled trial$).mp or controlled clinical trial$.mp or clinical trial$.mp</P>
<P>(b) human/ or nonhuman/ or animal/ or animal experiment/</P>
<P>(c) (b) not human/</P>
<P>(d) (a) not (c)</P>
<P>For the updates the following subject headings and text words were used:</P>
<P>1. Randomized Controlled Trial/<BR/>2. Controlled Clinical Trial/<BR/>3. randomized.ti,ab.<BR/>4. placebo.ti,ab.<BR/>5. randomly.ti,ab.<BR/>6. trial.ti,ab.<BR/>7. groups.ti,ab.<BR/>8. drug therapy.sh.<BR/>9. or/1-8<BR/>10. Human/<BR/>11. 9 and 10</P>
<P>Finally, searches were combined as (1) AND (2) AND (3) AND (4).</P>
<P>[mp = title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name; sh = subject heading; ti,ab = title, abstract; / = Emtree term; $=zero or more characters; RCT = randomised controlled trial; CCT = controlled clinical trial].</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-05-25 15:04:53 +0200" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>